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Inflammatory Bowel Disease (IBD) 
IBD is a chronic illness, with two main subtypes; Crohn’s disease (CD), and 
ulcerative colitis (UC). Predominant symptoms include pain, fatigue, frequent diarrhea, rectal 
bleeding, weight loss and perianal disease. Psychological symptoms including distress, 
anxiety and depression are also common. IBD is an organic disease characterised by physical 
alterations in the bowel. This is different to functional gut disorders like Irritable Bowel 
Syndrome (IBS) whereby patients experience symptoms without observable inflammation 
and damage to the gut. Individuals with IBD have significant comorbidity with IBS and are 
more likely to suffer from IBS than the general population (Farrokhyar et al., 2006). Study 
estimates range from 39% comorbidity with IBS (Halpin & Ford, 2012), up to 80% 
comorbidity with functional gut disorders (Mikocka-Walus et al., 2008). 
Incidence and prevalence 
IBD is characterised by its early onset, with some studies estimating 25% of patients 
with IBD are diagnosed before the age of 18 (Sawczenko et al., 2001; CCA, 2016). 
Epidemiological studies show that peak onset is between the age of 25-34 (Binder, 2004). 
Over 5 million people globally have been estimated to suffer from IBD (Burisch & 
Munkholm, 2015) and Australia has one of the highest incidence rates in the reported 
literature with an overall incidence rate of 29.6 per 100,000 (Wilson et al., 2010), 
alternatively stated as 1 in 250 persons aged 5-40 (PWC, 2013). Although IBD incidence is 
low, due to the lifelong nature of the illness, and its early onset, its prevalence is much 
greater. Currently there are 80,000 people with IBD in Australia, and this is predicted to 
increase to 100,000 by 2022 (CCA, 2019). Improving health care systems for IBD in 





Treatment for IBD 
 There is no cure for IBD, and it is managed largely through the long-term use of 
medications and/or surgery. IBD is a remitting-relapsing illness, meaning that individuals 
often experience times of remission intercepted with periods of relapse, and this IBD course 
varies from person to person. Medications such as immunomodulators and biologics are 
effective at controlling the symptoms of IBD, and in some cases can prevent the need for 
surgery, however they are not easily available and are expensive (GBD 2017 IBD 
Collaborators, 2019). Steroids are also commonly used to induce remission; however long-
term use of steroids as a maintenance therapy is not recommended and continued steroid use 
indicates poorly controlled disease activity (Carter, Lobo & Travis, 2004). Overall, 60-75% 
of CD patients and 25-30% of UC patients are estimated to require surgery at some point in 
their lifetime (Cosnes et al., 2011). Surgery can involve removing sections of the bowel, or 
emergency colectomies where the entire colon is removed (Samuel et al., 2013). Individuals 
are therefore placed with a heavy burden of managing the unknown course of their IBD, 
given the chronic nature of the illness.  
Aetiology 
Although the precise cause of IBD is unknown, genetic, bacterial, immunological, and 
environmental factors are thought to be involved. Jostins and colleagues (2012) conducted a 
meta-analysis with over 75,0000 cases and controls which confirmed the identification of 163 
IBD loci. A loci specifically indicates the location of a genetic marker. Despite this, no 
specific gene has been implicated to cause IBD, and the concordance amongst identical twins 
has been found to be as low as 20% (Halme et al, 2006). Therefore, epigenetics – an interplay 
between genetic susceptibilities and environmental triggers – provide a more likely 
aetiological pathway for the development of IBD.  
9 
 
In their recent review Glassner and colleagues (2020) highlighted the complexity and 
importance of the microbiome and gut bacteria in IBD; specifically, the microbiome may 
play a causal role in the pathogenesis of inflammatory responses seen in IBD, via 
commination with the immune system. Further, a recent case control study indicated that 
gastrointestinal infections which impact the microbiome drastically increase the chance of 
developing IBD (Axelrad et al., 2019).  
Despite the evidence indicating that the microbiome plays a significant role in IBD, 
interventions targeted at influencing the microbiome lack sound evidence due to poor 
consistency in studies, study design and mixed results (Glassner et al. 2020). Such 
interventions may include probiotics, however, a recent systematic review and meta-analysis 
indicated that more evidence is needed (Derwa et al., 2017). 
Environmental factors play a strong role in mediating the disease occurrence 
(Ananthakrishnan, 2013) to the extent that in a migrant population, IBD incidence resembles 
not the country of origin, but the country of residence (Williams, 2008). Environmental 
factors such as smoking for CD, diet, antibiotics use, pollution and sedentary lifestyle have 
all been implicated in IBD onset (Lawrance et al. 2013; Neuman & Nanau, 2012). It is these 
environmental factors which likely mediate the association between socioeconomic status 
and IBD (Ng et al. 2013; Neuman & Nanau, 2012).  
Psychological factors such as distress have been shown to intercept disease activity 
with studies illustrating bidirectional links between psychological state and disease activity 
(Gracie et al, 2018). However, whether psychological factors play a causal role in the 
aetiology is difficult to discern. Therefore, further research is needed to identify precisely the 
complex bio-pathophysiological mechanisms of IBD, which appears to be comprised of 
complex biological, environmental, psychological and social factors (Boyapati et al., 2015), 
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The Brain-Gut Axis (BGA) 
 The BGA is a term which broadly encompasses the bidirectional system of 
communication between the brain and the gut. The BGA challenges the biomedical notion 
that there is a strict dichotomy between mind and body, and that physical ailments and 
illnesses are considered to be limited to the body alone.  
The gut does not exist in isolation, and despite being known for its ability to digest 
food, absorb nutrients and excrete waste, the gut plays a crucial role in interacting with the 
brain by exchanging information along a number of neuroendocrine and neuroimmune 
pathways (Allen et al., 2017). A recent study found evidence that bacteria in the gut exchange 
signals to a part of the brain called the serotonergic system to promote the health of the 
intestine (Fung et al., 2019). The gut also plays a key role in immune function, hormones, and 
the enteric nervous system (Mater et al., 2015), alongside interacting with the central and 
autonomic nervous system, the body’s stress response system and the rest of the 
gastrointestinal system (Bonaz & Bernstein, 2013). 
 Finally, it has been widely cited that the gut is responsible for producing up to 80% 
of the body’s serotonin and storing up to 95% of the body’s serotonin, with recent research 
indicated that gut microbiota influences the production of serotonin in the gut (Hata et al., 
2017). Serotonin is an important neurotransmitter responsible for regulating mood, appetite 
and sleep, and is a key component of commonly used antidepressants, Selective Serotonin 
Reuptake Inhibitors (SSRI’s).  
Biopsychosocial links in IBD 
The biopsychosocial model posits that biological, psychological and social factors all 
interconnect and influence the development of illness and psychological problems (Engel, 
1977). This contrasts to the traditional biomedical approach which focuses on physical 
symptoms alone, without consideration of psychological or social contributors to illness. IBD 
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is a biopsychosocial illness, which affects a person’s physical, psychological and social 
wellbeing.  
Physical 
Patients with IBD experience pain, frequent diarrhoea and fatigue. Persistent pain has 
significant impacts on psychosocial functioning and QOL in individuals with IBD (Morrison 
et al., 2013). Pain persists in around 20% of IBD patients in remission (Bielefeldt et al., 
2009). Poorly managed pain is also associated with reduced health-related quality of life 
(HRQOL) (Schirbel et al., 2010; Palm et al., 2005).  
In addition to frequent diarrhoea, which can keep people bound to the bathroom, an 
estimated 24% of patients experience incontinence (Norton et al, 2013), which can occur 
despite patients being in remission (Keogh & Burke, 2017).  A cross-sectional survey by 
Keogh and Burke (2017) (n=117) identified that 70% of respondents struggled to reach the 
toilet in time in the three months prior to the study and that levels of anxiety and depression 
were higher in those who had experienced incontinence.  
A systematic review (n=254) by Van Langenberg & Gibson (2010) estimated the 
prevalence of fatigue to be up to 48% in patients in remission and up to 86% in moderate-to-
severe Crohn’s disease. However, this estimation was confounded by poor validation of 
measures, and ill-defined cut off scores.  
Psychological 
Patients with IBD are more likely to experience anxiety and depression. In their 
systematic review, Mikocka-Walus and colleagues (2016) found 19.1% of individuals with 
IBD experienced anxiety, and 21.2% experienced depression in comparison to the general 
population where 13.4% experienced depression, and 9.6% experienced anxiety. During 
times of acute illness upwards of 66.4% of patients with IBD experience anxiety, and 34.7% 
experience depression (Mikocka-Walus et al., 2016). 
12 
 
The literature has discussed the interconnection between psychological distress, 
anxiety and depression and disease onset and activity in IBD. Individuals with a history of 
depression are more likely to develop IBD (Frolkis et al, 2019) and depression places patients 
with IBD at increased risk for relapse (Kochar, 2018). A large observational cohort study 
(n=10,834) by Ananthakrishnan and colleagues (2013) found the presence of anxiety and/or 
depression increased a patient’s chance of surgery and hospitalisation. This has been further 
highlighted by Wong and colleagues (2019) in their retrospective cohort analysis (n=331772) 
which found that depression was associated with increased costs (an average increase of 
$17706), and emergency department presentations. Further, depression has been found to 
predict prolonged length of hospital stay in paediatric IBD even when controlling for disease 
severity (Patel et al., 2019).  
In their longitudinal study (n=405), Gracie et al. (2018) found support for the 
bidirectional nature of anxiety and IBD activity. Clinical IBD activity was significantly 
associated with the development of abnormal anxiety scores. Similarly, inactive IBD and 
abnormal anxiety scores at baseline were associated with later flares of activity, escalation of 
therapy and need for steroid administration.  
Individuals with IBD experience consistent, long-term stress (Mittermaier et al. 2004; 
Levenstein et al. 2000). The remitting, relapsing and unpredictable course of IBD is a stressor 
in itself (Sexton & Bernstein, 2015; Keeton et al., 2015) with flare ups triggering higher 
levels of acute stress (Graff et al. 2009). Targownik et al. (2015) conducted a population-
based study (n=478) which found that while perceived stress was associated with 
symptomatic activity, it was not associated with intestinal inflammation. Yet, Bernstein and 
colleagues (2016) in another publication from the same study, concluded that stress remained 
stable despite changes in disease activity.  
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Chronic long-term stress has been identified as a relapse risk factor for UC 
(Levenstein et al., 2000; Jaghult et al., 2013). Bitton and colleagues (2008) in their 
prospective cohort study found lower stress levels and less avoiding coping behaviours were 
associated with lower risk of relapse. A review of 11 longitudinal studies illustrated that 
stress and depression increased the chance of relapse, negatively influencing the course of 
IBD (Rampton, 2010). Further, perceived stress and distress have been found to be predictors 
of IBD re-occurrence (Sexton & Bernstein, 2015). Yet, a recent study by Lores and 
colleagues (2019) which trialled integrated psychological screening and intervention (n=335) 
and found psychological distress was not associated with disease activity. This latter finding 
fits with prior research which hypothesised that perceived stress as a construct is implicated 
in exacerbating symptoms only when the stress is symptomatic of the presence of depression 
and/or anxiety (Camara et al, 2011). Ultimately due to the observational nature of most of the 
study designs employed in the literature conclusions determining the role of stress and 
causality are limited. 
Although the link between psychological distress and IBD disease activity is difficult 
to disentangle, the relationship between stress, depression and inflammation in the gut has 
been established biologically in mice. An experimental study by Ghia and colleagues (2009) 
observed that when depressive symptoms were induced in mice, it reactivated dormant colitis 
and gut inflammation, and that administration of tricyclic antidepressant was associated with 
remission. A previous review by Mawdsley and Rampton (2006) concluded that animal 
studies provided strong evidence for the idea that chronic and acute stress play a role in IBD 
onset and relapse.  Therefore, despite animal studies lacking adequate transferability to 
humans, this research provides motivation for further research and understanding of the 





A meta-synthesis by Kemp and colleagues (2012) found people with IBD felt socially 
isolated due to incontinence. Jordan et al. (2018) conducted a qualitative study (n=25) which 
linked symptoms of anxiety to concerns about incontinence in social settings. A systematic 
review indicated that individuals with IBD may face social stigma which can impact 
HRQOL, however this has been identified as an area in need of further research (Taft & 
Keefer, 2016). In addition, perceived lack of understanding and stigma have been identified 
as themes associated with low mood (Jordan et al., 2018). 
Further, individuals with IBD have reported higher rates of unemployment and 
disability compared to control groups (Sewell & Velayos, 2013). Unemployment in people 
with IBD has been significantly correlated with lower QOL (Bernklev et al., 2006; 
Moradkhani et al., 2013). Physical symptoms of IBD can influence employment 
opportunities for patients’, with research showing that achieving remission for UC is 
associated with a three-fold increase in gaining employment (Reinisch et al. 2007). Patients 
reporting higher levels of fatigue are more likely to be unemployed (van Langenberg & 
Gibson, 2014.) Employment is an important factor for mental health broadly, with research 
showing that unemployment is associated with higher rates of mental distress (Paul & Moser, 
2009). Difficulties fully engaging with work can further exacerbate the financial burden of 
living with IBD, and the costs associated with managing the illness.  
Therefore, the unpredictable nature of IBD can impact social factors such as social 
connection, and involvement alongside relationships, and engagement in work and study, all 
of which can ultimately result in a reduced QOL (Jones et al, 2018). 
Quality of life (QOL) 
Health-related QOL (HRQOL) is an important outcome for people with IBD, as it 
measures an individual’s perceived physical and mental health over a period of time (WHO, 
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2020). Individuals with IBD have lower HRQOL than healthy controls (Verma et al., 2018). 
Reduced QOL is associated with increased hospital admissions (Jones et al, 2018). 
Qualitative research has also underscored the importance of QOL which has been identified 
as a key concern for patients with IBD (Keeton et al., 2014). Therefore, given IBD is a 
biopsychosocial illness, making efforts to improve not only biological symptoms of IBD, but 
broader psychosocial factors which implicate HRQOL is an important goal for the treatment 
and management of IBD. A healthcare system which integrates multidisciplinary care in 
order to address the broader factors beyond biological components, as discussed in this 

















Figure 2 Engel's biopsychosocial model applied to inflammatory bowel disease 
16 
 
Evidence for psychological interventions in IBD 
Disease activity 
Despite psychotherapies such as gut-directed hypnotherapy and antidepressants being 
increasingly cited as effective at reducing physical symptoms of functional gut disorders 
(Ford et al., 2014), the literature is equivocal on how far psychological interventions can 
change the course of IBD disease activity. Qualitative research has identified that patients 
with IBD self-report improvements in disease course with psychotherapy (Mikocka-Walus et 
al., 2013). Yet, a systematic review and meta-analysis of 14 randomised controlled trials 
(RCT’s) by Gracie and colleagues (2017) found that psychological therapies did not have any 
effect on disease activity, despite finding that CBT improved QOL and depression in the 
short term. 
Cognitive-behavioural therapy (CBT) 
A multicentre RCT conducted in Amsterdam and the Netherlands by Bennebroek and 
colleagues (2017) found that disease specific CBT was effective at improving QOL and 
decreasing symptoms of anxiety and/or depression, particularly in patients with poor QOL. 
Despite these findings, a subsequent study by Stapersma, and colleagues (2018) found that 
disease specific CBT for subclinical anxiety and depression was no more effective than 
treatment as usual (TAU) at reducing anxiety or depressive symptoms. The participants 
included in the study did not experience clinical levels of anxiety and/or depressive 
symptoms, and overall psychological and physical burden of disease was low for this patient 
group. This may explain why disease specific CBT failed to reduce anxiety and/or depressive 
symptoms more than TAU.  
An American pilot study (n=9) by Reigada and colleagues (2013) found that 
integrating disease specific concerns into CBT for adolescents with comorbid IBD and 
anxiety was effective at reducing pain, anxiety and disease severity. However, this study was 
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limited by the small sample size and has limited merit. A more recent pilot RCT (n=174) by 
Mikocka-Walus and colleagues (2015) found CBT did not improve disease activity but did 
improve QOL and reduce distress associated with IBD. 
Hypnotherapy, relaxation, stress management and other interventions 
An RCT (n=54) by Keefer and colleagues (2013) found that gut-directed 
hypnotherapy was effective at prolonging clinical remission in patients with inactive UC. A 
systematic review of 15 papers from 1987 to 2015 by Norton et al. (2017) identified a lack of 
research for pain as an outcome measure but drew tentative conclusions that relaxation and 
cognitive strategies may effective at reducing abdominal pain. Vogelaar and colleagues 
(2011) in their RCT (n=29) compared the efficacy of problem focused therapy (PFT), 
solution focused therapy (SFT) and treatment as usual (no psychological intervention) to 
reduce fatigue for patients with IBD. The SFT group saw 85.7% of patients improve on 
measures of fatigue, in comparison to 60% in the PST and 45.5% in the TAU group. 
An RCT (n=45) by Garcia-Vega, and Fernandez-Rodriguez (2004) found that a stress 
management intervention reduced tiredness, and abdominal pain when compared to medical 
treatment alone, and these results were still present at 12-months. However, this study 
selected only participants in non-active stages of illness, and is therefore limited in its 
generalisability. Another RCT (n=14) investigating the effect of a Breathing, Movement and 
Meditation workshop found significant improvements on quality of life, physical symptoms 
as measured by c-reactive proteins and depressive symptoms (Gerbarg et al., 2015). 
However, this study was limited by its small sample size. However, Boye and colleagues 
(2011) (n=114) found that stress management (including problem solving, psychoeducation 





Psychological interventions overall 
In 2011 a Cochrane review identified that studies investigating psychological 
interventions in IBD were of low methodological quality, and although was some evidence 
that adolescents or those who were emotionally vulnerable may benefit from psychological 
interventions, the review could not recommend psychotherapy for patients with IBD due to a 
lack of evidence supporting its efficacy (Timmer et al., 2011). Psychological interventions 
used in the research have not targeted specific disease related stressors which may be one 
reason for the lack of effectiveness of these interventions overall in the literature (Camara et 
al., 2011). 
Integrated multidisciplinary models of care 
Despite the well-established biopsychosocial underpinnings of IBD, it has traditionally 
been managed as an acute illness in a biomedical model of care. This means that patients 
receive treatment when they are actively experiencing an IBD flare and are not engaged in 
treatment when they are in remission. Acute management based on a biomedical model 
ignores the psychosocial mechanisms in IBD and is not able to meet the needs of chronically 
ill patients (Wagner et al., 1996). In doing so, it leaves patients vulnerable to further damage 
to the gut given the chronic nature of the disease (Pariente et al., 2011).  
In contrast to biomedical healthcare, an integrated model of care emphasises a 
coordination of services, organisations, inputs and deliveries, based on patient care, diagnosis 
and treatments (WHO, 2001). Since their 2001 position paper, the WHO has recommended 
integrated care and highlighted specifically its need for patients with chronic illness (Gröne et 
al., 2001). 
Integrated care aims to exchange expertise so that different aspects of a patient’s 
treatment can work together (Shaw et al., 2011). This coordination of services is specifically 
suited to managing chronic illness due to the biopsychosocial impact of IBD and the 
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biopsychosocial approach that integrated care affords. Further, multidisciplinary care 
involves multiple healthcare professionals collaborating together to meet the multifaceted 
needs of a patient (Zwarenstein et al., 2009). Australian IBD Standards recommend that an 
IBD patient have access a multidisciplinary team inclusive of a psychologist, dietician, and 
IBD nurse among others (CCA, 2016).  
Mikocka-Walus and colleagues (2012) highlighted common features of integrated models 
of care for IBD. These include; mechanisms for active follow up for IBD patients (especially 
if these patients are known to be experiencing difficulties), patient education about IBD, 
encouragement of involvement in consumer organisations, comprehensive assessment of 
biopsychosocial functioning of patients at the point of entry into the healthcare system, and 
IBD dedicated nurses knowledgeable in IBD. 
An Australian qualitative pilot study conducted with both patients and staff in a 
multidisciplinary primary healthcare centre (n=29) explored implicit descriptions of 
integrated care (Banfield et al, 2017). Their analysis indicated patients rely on relational 
aspects of outcomes and care, in contrast to existing frameworks of integrated care which 
have been influenced by organisational views. Their findings outlined patients’ perceptions 
of integration, included; increased co-location of services, retaining established relationships, 
and ease of access to services. Continuity of care was discussed in particular in relation to 
completeness of records, and patients discussed person-focused care in relation to being 
given a choice of appointment time.  
Multidisciplinary care to reduce diagnostic delay 
A recent clinical update published by the Gastroenterological Society of Australia, 
intended for General Practitioners (GP’s) in Australia highlighted that diagnostic delays for 
IBD frequently occurred due to GP’s not suspecting IBD as a potential cause (Clinical 
Update for General Practitioners and Physicians: IBD, 2018). Diagnostic delays are 
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associated with poorer patient outcomes including increases in the risk of intestinal surgery 
(Lee et al., 2017). 
A multidisciplinary team can enable different specialists to work together to quickly 
ensure that mutually exclusive diagnoses and conflicting treatment plans are not prescribed, 
prevent delays in diagnosis or misdiagnoses especially between the different subtypes of 
IBD, and reduce unnecessary examinations which can cause distress (Phan et al., 2012). 
Early intervention has previously been shown greatly improve quality of life and reduce the 
cost or need for radical surgery and emergency hospitalisation (D’Haens et al., 2008).  
Screening and access to psychological care 
In a recent large cohort study (n=8222), standardised screening and early psychological 
intervention was highlighted as a priority, to improve paediatric IBD patient outcomes (Patel 
et al., 2019). Another recent study by Lores and colleagues (2019) found 90% of IBD 
patients in their study believed that screening for psychological distress was an important 
resource in ambulatory IBD care. They identified that predictors of psychological distress 
included; recent diagnosis, younger age, low adherence to medication and use of pain 
medications; these predictors may assist in identifying patients in need of psychological 
support. Further, engagement in psychological services is enhanced when it is delivered in an 
in-service integrated model of care than compared with delivery externally, with Lores and 
colleagues (2019) also finding a six-times increase in engagement for those treated in-
services. 
Despite this, a recent Australian cross-sectional study (n=731) by Mikocka-Walus and 
colleagues (2020) found that only 12% of participants had access to a psychologist, and only 
one-third of participants reporting access to an IBD nurse or dietician. The large majority of 
participants (97%) reported access to a gastroenterologist. Therefore, despite healthcare 
providers support for integrated multidisciplinary care and its demonstrated efficacy, these 
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results indicate that for many participants multidisciplinary care is lacking, and a biomedical 
model persists whereby patients have access to a specialist one-on-one without holistic access 
to ancillary services.  
The efficacy of integrated multidisciplinary care 
The cost of IBD in Australia has been estimated in 2013 to have been $2.7 billion dollars 
(PricewaterhouseCoopers, 2013), with a loss in work productivity at that time approximately 
$361,499,232 per year. Individuals with IBD have greater health care utilisation costs 
compared with control groups (van Langenberg et al., 2010). A large proportion of the 
economic costs of IBD is due to surgery and hospitalisation (Bodger, 2002; Cohen et al., 
2010). Episodic and reactive care where patients are only seen and cared for during acute 
flares of the disease or where there are serious complications is costlier than an integrated 
model of care which aims to reduce the need for emergency hospitalisation and surgery (Sack 
et al., 2011). Integrated care has been shown to improve patient outcomes such as reduce 
hospital admission rates, and other related comorbidities and complications (Mikocka-Walus 
et al., 2012; Schoenfeld et al., 2018). A prospective cohort study (n=461) before and after the 
implementation of an integrated care intervention was conducted by Sack and colleagues 
(2012). They demonstrated that integrated care significantly reduced the cost of IBD via 
fewer hospital admissions, optimised treatment regimes, and reduced unnecessary testing.  
A recent quasi experimental study in United States found that a Total Care IBD program 
including the above specified specialists working in a multidisciplinary team significantly 
improved QOL, disease activity and reduced unplanned treatment (Regueiro et al., 2018). 
Research has highlighted that early management of symptomatic disease reduces admissions 
to hospital and surgery rates, thereby reducing costs (D’Haens, et al., 2008; van Langenberg 
et al., 2010). Guidelines on care for IBD have stressed the importance of rapid access to care 
– especially specialist care – in order to prevent IBD illness severity from escalating at which 
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point costs through emergency surgery and individual suffering and distress increases (Carter 
et al., 2004). 
Phan and colleagues (2012) in their Australian prospective cohort study found that within 
18 months of a dedicated IBD service being implemented patient outcomes were improved as 
evidenced by decreased hospitalisations, steroid and opiate use. Lores and colleagues (2019), 
also demonstrated that when psychological intervention and screening was done in an 
ambulatory in-service setting in an Australian tertiary hospital, it significantly reduced 
emergency presentations and opiate use for those who participated in a psychological 
intervention. Access to psychological services is only one aspect of integrated care for IBD, 
yet Lores et al. (2019) demonstrated a reduced cost of $30,000 in a one-year period with 
integrated psychological services offered. In line with this, international guidelines for IBD 
recommend psychological support, to aid in improving the course of IBD (Häuser et al., 
2014). Despite this, research indicates that individuals are not being asked about their mental 
health (Bennebroek et al., 2012). 
Therefore, an integrated model of care where the individual is seen regularly during times 
of wellness is better able to improve quality of life and reduce complications and healthcare 
costs associated with the illness (Sack et al., 2012).  
IBD Standards of Care 
In 2016, Crohn’s and Colitis Australia published National Standards of Care for IBD (CCA, 
2016). These include high quality clinical care whereby patients have access to a 
multidisciplinary team, quick access to specialist care and when possible access to local 
delivery of healthcare, alongside patient education (CCA, 2016). The latter is supported by 
research outlining that greater IBD specific knowledge increases patient satisfaction, medical 
adherence and reduces levels of distress (Waters et al., 2005). In addition, past survey estimates 
in the literature estimate that only 5% of healthcare providers claim to use biomedical models 
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of care, with most believing IBD services should be integrated and involve multiple specialists 
(Mikocka-Walus et al, 2014).  
Despite the literature outlining the efficacy of multidisciplinary care, healthcare 
professionals reporting their preference for multidisciplinary care, and National Standards 
being published, research indicates that healthcare is falling short. Specifically, Mikocka-
Walus and colleagues (2020) recently conducted a cross-sectional study (n=731) comparing 
patient experiences of healthcare alongside National IBD standards and identified that 
National standards of IBD care were not being met. Specifically, many participants are 
experiencing delays in access to specialist care whist experiencing active disease, and a lack 
of access to multidisciplinary services. Specifically, their data indicated that up 68.2% of 
patients who experiences severe distress, are not engaged with a mental health clinician 
(Mikocka-Walus et al., 2019). 
Current limitations 
Recall biases and symptom-based measurement tools makes it difficult to discern or 
prove empirically the nature of the relationship between mental health (stress, depression 
and/or anxiety) and IBD symptom severity (Bernstein et al. 2010; Singh et al. 2009). Further 
limitations surround the methodologies used, including establishing cause and effect within 
cross-sectional studies (Jaghult et al., 2013). Another confounder when consuming the 
literature with regards to IBD and healthcare is that studies emerge from different countries, 
and these countries often have different healthcare systems which may confound the 
applicability or generalisability of results to an Australian context.  
Future research 
One of the core principles of integrated care is patient input and involvement in 
service development, to better enable provision of services, which considers patient values, 
preferences and culture (Mikocka-Walus et al., 2012; 2013). Therefore, an Australian study 
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examining the patient perspectives on IBD healthcare is an area lacking in research and 
needing investigation (Mikocka-Walus et al., 2020). 
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 Background & Aims: Inflammatory Bowel Disease (IBD) is a biopsychosocial illness. 
The prevalence of IBD is increasing in Australia, which presses the need to improve healthcare 
for patients with IBD. To date, no study has examined the views or preferences that Australian 
IBD patients have for their healthcare. This article reports on Australian patient’s with IBD 
perspectives and preferences for healthcare.  
Methods: Patients with IBD (n=477) responded to an open-ended survey question 
‘What changes if any would you make for your IBD healthcare? And why?’ within a larger, 
previously conducted cross-sectional survey. These previously unanalysed responses were 
content analysed with open coding using NVivo. 
Results: Nine categories were formulated. Respondents expressed a desire to have 
greater access to (1) multidisciplinary services (17.70%), (2) proactive healthcare with 
increased follow up and long-term care planning (8.50%), and (3) treatment, services and 
specialist care (16.40%). Participants also requested (4) better communication (23.52%), and 
(5) whole of person care (10.24%).  In addition, participants wanted (6) health promotion (i.e. 
public awareness and support groups) (10.42%).  Finally, a proportion of participants were (7) 
happy with their healthcare (9.72%). Two minor categories – (8) administrative issues, (2.34%) 
and (9) improving the hospital experience also emerged (1.04%).  
Conclusions: The results support existing research outlining multidisciplinary care is 
better suited to meet the needs of patients with IBD. Healthcare professionals should focus on 
facilitating patients’ access to multidisciplinary services (i.e. psychologists, IBD nurses and 
dieticians), and increasing proactive care (i.e. follow up and long-term care planning). Asking 
patients about their mental health and communicating respectfully should also be priorities.  
(Keywords: inflammatory bowel disease, biopsychosocial healthcare, models of healthcare, 




Multidisciplinary integrated healthcare  
The World Health Organisation has defined integrated care as; “the organisation and 
management of health services so that people get the care they need, when they need it, in ways 
that are user friendly, achieve the desired results and provide value for money.”1 Therefore, an 
integrated healthcare system coordinates different services involved in patient care. 
Multidisciplinary care involves promoting teamwork and collaboration amongst different 
healthcare professionals who are involved in the care of a patient.2,3 The importance of 
integrated, multidisciplinary care has long been recognised as important in the management of 
a range of chronic and other illnesses,4,5 
including heart transplant,6 cancer7 and 
diabetes8 among others. Multidisciplinary care 
is particularly suited to respond to the needs of 
patients with inflammatory bowel disease 
(IBD) given its chronic nature, wide 
extraintestinal manifestations,9 and 
psychosocial factors involved.10 A study of 
healthcare professionals (i.e. 
gastroenterologists, nurses, psychologists, and 
dieticians) revealed that most healthcare 
professionals believe that IBD care should be 
fully integrated, involve input from 
multidisciplinary services in specialist clinics, and be easily accessible.11  
What You Need to Know 
Background 
IBD is a biopsychosocial illness. Studies have 
illustrated integrated biopsychosocial healthcare 
can reduce costs and improve patient outcomes. 
However, little is known about the patient 
perspective on what healthcare is wanted.   
Findings 
A content analysis (n=477) of IBD patients’ 
responses to the open-ended question “What 
changes would you make if any for your IBD 
healthcare? And why?” showed 9 categories centred 
around biopsychosocial healthcare. 
Implications for patient care 
Patients with IBD want access to multidisciplinary 
services (including psychological care) as well as 
proactive care (i.e. follow up). 
47 
 
In line with this, Australian IBD Standards (2016)12 outline that multidisciplinary care 
is the best approach for managing IBD. These guidelines outline that the multidisciplinary team 
should include; a gastroenterologist with IBD training, a colorectal surgeon with IBD training, 
a specialist IBD nurse, an accredited practising dietician, a psychologist, a stomal therapist, a 
radiologist, histopathologist and pharmacist with an interest in IBD, and telephone helplines. 
IBD care should also involve healthcare professionals knowledgeable in IBD engaging 
collaboratively to coordinate care in a proactive manner.12 This collaboration is integral to an 
integrated multidisciplinary model of care.13 Multidisciplinary, integrated care should also 
include follow-up, patient centred care, patient education about IBD, and a comprehensive 
assessment of a patient’s biopsychosocial functioning when they enter the healthcare system.14 
The benefits of multidisciplinary, integrated care for IBD have been demonstrated 
practically in numerous studies. A prospective cohort study showed that when patients received 
a 24/7 nurse telephone helpline, regular monitoring of blood test results, scheduled follow up, 
patient education and information, encouragement to join Crohn’s and Colitis Australia (CCA), 
and other proactive changes, there was a significant reduction in healthcare cost and disease 
burden, and fewer inpatient admissions.15 In addition, studies have shown that implementing 
IBD trained nurses, telephone helplines, information and education leaflets, newsletters, and 
encouragement to join CCA, increases patients’ IBD knowledge, medication adherence, 
satisfaction with care, and quality of life.16 Proactive changes to healthcare have been also been 
found to reduce symptoms of anxiety and depression, as well as hospital admissions.16 
The implementation of telephone services alone can lead to significant improvements 
for patient care. An Italian prospective observational study17 (n=1867) found that telephone 
helplines reduced hospitalisation, and eased communication between the patient and 
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physicians. Further, their study estimated that one-third of calls were regarding non-medical 
issues, and these patients would otherwise have attended ambulatory settings.17 
In their longitudinal study, Martinez-Vinson and colleagues (2020) observed that 
implementing a dedicated IBD nurse into multidisciplinary care reduced hospitalisations, 
overall costs and promoted outpatient care.18 Nurses are placed in a position that enables them 
to identify psychological distress in IBD patients.19 The role of IBD nurses includes 
communicating with patients, pain management, and assisting with managing fatigue and 
incontinence, as well identifying issues such as nutritional or sexual issues and referring on.20 
An Audit of IBD Care in Australia outlined that it was more common for patients to be provided 
with information and materials when there was an IBD nurse implemented as part of the IBD 
service, highlighting their important role in patient care.21  
Further, given the high rates of anxiety and depression in patients with IBD, providing 
access to psychological therapy is important for improving quality of life and management of 
disease activity in IBD.22 Early identification of psychological distress has been highlighted as 
important to patient outcomes.23 A recent prospective study (n=335) showed that patients with 
psychological distress who engaged in psychological intervention were less likely to present to 
emergency, providing support for the integration of psychological care into the management 
of IBD to reduce costs and healthcare utilisation.24 
Dieticians are also integral in IBD care, given the high rates of nutritional deficiencies, 
malnutrition and weight loss in patients with IBD,25 and the use of enteral nutrition in the 
treatment of IBD.26 Yet, quality information regarding IBD specific dietary information is 
variable,27 and as will be outlined below, patients’ access to dieticians is lacking. 
Finally, follow up is important given the remitting/relapsing nature of IBD, in order to 
maintain remission or to intervene early before disease progresses and further gut damage 
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occurs, and to improve patient experience.28 Despite this, follow up by gastroenterologists in 
perioperative Crohn’s is inconsistent, and coordinated multidisciplinary care is lacking.29  
Typical model of care for IBD 
Despite the evidence base for multidisciplinary care in relation to IBD, IBD is typically 
treated within a specialist-led biomedical model of healthcare. In this biomedical model of 
healthcare, the patient is seen during times of acute illness, and these interactions address 
biological aspects of illness. This is problematic as it does not address psychological and social 
factors which are important factors in a patient’s quality of life. This reactive type of healthcare 
where acute flares and serious complications trigger patient care and intervention often results 
in further gut damage for patients given the chronic nature of the disease.30  
In their systematic review (21 studies included) Prasad and colleagues (2019) found that in 
IBD care overall, there is an overreliance on gastroenterologists, and nurses, with little 
utilization of other primary healthcare providers such as general practitioners and allied health 
providers such as psychologists or dieticians.31 This indicates that despite the theoretical and 
practical evidence for the efficacy of multidisciplinary care, specialist led care is still being 
heavily used in the management of IBD.  
In line with this, an Australian Audit of IBD care in Australia highlighted that only 1% of 
patients had access to a full IBD team, 39% had access to an IBD nurse, 38-40% had nutritional 
screening on hospital admission, 4% had access to a psychologist, and only 28% of patients 
had a protocol in place for managing severe ulcerative colitis flares.21 Therefore, despite 
mounting evidence for the efficacy of multidisciplinary integrated care, currently studies 





Patient-centred care and adequate communication. 
Patient centred care includes patient participation and involvement, and a cohesive, genuine 
doctor-patient relationship where patients collaboratively decide on treatments.33 An integral 
part of patient centred care also includes adequate explanation and information provision about 
IBD.34 Recently Park and colleagues (2020) found that disease-related knowledge could be 
important to enhance patient-management and coping with disease, therefore reducing the need 
to escalate therapy in IBD.35 Colombara and colleagues (2015) demonstrated that greater IBD 
related knowledge had the potential to reduce costs,36 and studies have found that illness 
perceptions, often influenced via education and doctors communications, can influence quality 
of life in patients with IBD.37 
Despite this, studies suggest that communication and patient centred care is lacking in IBD. 
Rubin and colleagues (2017) found that in their qualitative analysis of physician and patient 
interactions in Europe and the U.S., most of the consult involved quantification of symptoms 
with little discussion of the psychosocial impacts of illness.38  Rarely did the physicians 
articulate collaborative goals with patients, and terms such as “inflammation” were used 
frequently with little evidence of patient understanding or physician explanation. 38 Ghosh and 
Mitchell (2007) (n=5576) identified that while nearly half of doctors in Europe did not initiate 
a conversation around quality of life with patients, 86% of patients would have liked to try a 
new type of treatment, and 56% of patients did not have any new treatments discussed with 
them.9 In their qualitative study, Lai and colleagues (2019) reported that patients explained 
there was a delay in care, inadequate communication, and a perceived lack of control over 
disease management.39 In the study, patients described feeling as though there was no long-
term care plan, and they were just switching from treatment to treatment. Baars and colleagues 
(2010) in their survey (n=1,067), found that 81% of IBD patients found it very important to be 
51 
 
actively involved in the decision-making process, and when asked about how treatment could 
be improved 50% stated fairer and closer collaboration with their doctor.40 A European study 
(n=4670), investigating IBD patient’s experiences outlined that in addition to confirming the 
continued biopsychosocial impact of IBD; 67% of patients had to visit the emergency 
department prior to diagnosis; 64% wanted their specialist to ask more questions; and 54% 
stated they did not get to communicate something important to their doctor.41 
Additionally, good doctor patient-communication includes expressions of empathy. A 
German study by Chiapponi and colleagues (2016) (n=121) identified that women experienced 
greater feelings of embarrassment when discussing IBD related symptoms with their doctor.42 
Their study also posited that physician empathy is a source of support for patients given that 
there was a significant correlation between participants level of subjective burden and ratings 
of the importance of physician empathy.42 
Preliminary studies  
The current study builds on two prior publications. Firstly, Mikocka-Walus and colleagues 
(2019) examined the needs and access to psychological care alongside the prevalence of 
distress in Australian IBD patients.43 Only 15.2% had been asked about their mental health 
despite hald of the participants reporting psychological distress. Access to services were also 
lacking with only 12.2% reporting access to a clinician, while 68.2% of participants who scored 
in the severe distress range on the K-10 were accessing clinician.  Their study also observed a 
significant association between psychological distress and frequency of hospitalisation, disease 
activity, pain, fatigue and fistula and perianal disease. 43 
A second study by Mikocka-Walus, Massuger, Knowles, et al (2020)44 assessed the 
experience of healthcare against national standards. They found that actual health service 
experience falls short of national standards specifically regarding access to multidisciplinary 
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care, responsiveness, choice in care and clinical communication, and that patients are 
experiencing active disease, in a healthcare system that is not responsive, and where patients 
are not being afforded adequate patient centred care. Specifically, many participants indicated 
they had to wait more than two weeks to access specialist care. This goes against Australian 
IBD Standards, which outline that patients experiencing acute relapse should have access to 
specialist advice within 5 days. Only 50% had access to telephone helplines and while two-
thirds had a choice in their treatment, 51% wanted to be more involved, reinforcing the need 
for more proactive patient centred care. Of interest, despite healthcare falling short of IBD 
Standards, 74.8% of participants reported being satisfied with their healthcare. This indicates 
that patients are unaware of the IBD Standards of Care.12,44 
The current study 
When treating IBD, integrated models of healthcare has been demonstrated 
theoretically and practically to improve patient outcomes and to be more cost effective.15 
Currently, standards of healthcare are falling short, and patients with high levels of 
psychological distress, and active disease are still facing barriers to access multidisciplinary 
care.43,44 However, despite this no prior study has investigated what type of healthcare 
Australian patients with IBD want.  
Therefore, the nature of the current project was exploratory, with the guiding purpose 
to investigate what Australian IBD patients want for their healthcare. A content analysis was 
contextually guided by this aim and used responses to an open-ended question from a previous 
study conducted by Mikocka-Walus and colleagues.43,44 
Further as outlined in the Australian IBD Standards (2016), part of maintaining patient-
centred services involves giving patients the opportunity to give feedback and contribute to 
service development (standard C2), as well as involve patients in service improvement (C5). 
Therefore, although it has been identified that current healthcare for IBD falls short of National 
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Standards of Care (2016), a study exploring what IBD patients would like to change has yet to 
be conducted.12 The current study addresses this gap by capturing patients’ desired healthcare. 
Method 
Ethics  
The study was approved by the Deakin University Human Ethics Advisory Group 
(HEAG-H 85_2018). Participation was voluntary and anonymous. 
Design 
 A cross-sectional survey was conducted. 
Participants 
Participants were recruited from Crohn’s and Colitis Australia’s mailing list and via 
social media channels. Advertisements were made in gastroenterology clinics via newsletters. 
A total of 731 participants completed the study, after 293 responses were removed due 
incomplete data. Of the 731 participants who completed the survey 477 provided either an 
open-ended response to the question ‘What changes would you make for your healthcare?’ or 
wrote a response in the final comment box. To be included in the study, participants needed to 
have a self-disclosed diagnosis of ulcerative colitis, Crohn’s disease, or indeterminate colitis, 
be above the age of 16, be an Australian resident or citizen, and be able to complete the study 
in English.  
Procedure 
 An anonymous survey was conducted via Qualtrics. Participants were invited to an 
online link which included a Plain Language Statement, and the survey. Initially the survey 
was reviewed by a small number of patients with IBD for face-validity. Finally, counselling 
numbers (Lifeline) were made available to participants at the conclusion of the study in the 





Responses to the open-ended survey question: “What changes would you make 
to improve your healthcare for your IBD? What are your reasons?” and responses 
included in an additional comment box were included in the content analysis.  
The computer software NVivo was used to aid in coding of the data. Open 
coding was carried out by one researcher. The nature of the content analysis was 
exploratory as no pre-existing theory-based categorisation matrix existed.45 Categories 
were derived from the data in an inductive manner where the data was specifically 
coded and then examined and categorised more generally with interrelated codes placed 
together.46 
The inductive approach included a preparation phase whereby the researcher read over 
and familiarised herself with the overall data set. During the preparation phase consideration 
was also given to the representativeness of the sample, and the amount which should be 
analysed. Given the research question and relatively small amount of data from the study the 
whole sample was analysed. The sample can be said to represent the population under 
investigation however there is a possibility that patients in remission, and who are not currently 
engaged in the healthcare system, or patients who for other reasons including a lack of access 
to internet were not represented in the sample.43   
The organisation phase then included openly coding the data into smaller meaning 
units, and then similar codes were collapsed to form categories of similar content. During this 
phase, initial concepts were identified by coding the responses line by line. Only manifest 
content was coded, and no hidden meaning (such as grammar and phrasing) was analysed or 
interpreted beyond the surface meaning. Codes collapsed into categories shared a broader 
meaning. For example, the two codes, wait times to see GP and wait times to see specialist 
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were collapsed to form the code ‘wait times.’ After this, categories were formed which 
encompassed similar codes groups. 
Each open-ended response could have a number of different codes, and some data was 
coded in two codes. Therefore, the count of the data exceeds the number of open-ended 
responses.  
Inter-rater reliability/trustworthiness 
A random sample of 20% of the codes were checked by two additional researchers 
(ACH and AMW). The coding structure (included in Appendix A) was also checked by both 
additional researchers. Ambiguities arose and were either resolved at meetings between the 
researchers (MF, ACH and AM), or it was agreed that given the overlapping nature of the 
categories, that codes could fit in more than one category. 
Results 
Demographic statistics are provided in Appendix A. The data was initially examined to 
see if there was a difference between participants who chose to provide an open-ended 
response, and participants who chose to leave the box blank. A chi-squared test of 
independence indicated that there was no significant difference between type of IBD (CD, UC 
or IC) and whether or not participants provided an open-ended response or comment, χ2 (2, 
N=731) = 1.965, p =.374. A Fisher’s exact test also revealed that there was no significant 
association between participants experiencing distress vs. no distress and choice to provide an 
open-ended response, F=1.965, p =.374, or between men, women and other gendered participants 
(F=1.811, p=.368).  
Categories  
Open coding resulted in the emergence of the following main categories; ‘better 
communication’, ‘multidisciplinary care’, ‘proactive care’, ‘access to treatment, services and 
specialist care’, ‘health promotion’, ‘whole of person care’, ‘happy with healthcare’, ‘improve 
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hospital experience,’ and ‘administrative issues.’ All categories and subcategories with sample 
codes and extracts can be found in a table Appendix B. In total, the count of total codes was 1,152. 
This is due to participants responses containing multiple codes, and some segments being coded 
twice, and therefore the number of codes exceeds the number of participants. A diagram of the 
categories and the codes contained is represented in Figure 1.  Where the sub-codes have been 
filled with colour, this indicates where a code could be considered to link or overlap with another 
category. The category percentages show what proportion of the total count of codes were 
attributed to that category; the percentages shown under the categories show what proportion of 





















The category of multidisciplinary care was defined as access, or increased access, to a range 
of healthcare professionals in addition to specialist care, and/or a desire for increased 
interdisciplinary communication between any or all of the health professionals. Multidisciplinary 
care accounted for 17.7% of the total codes.  Participants expressed a desire to have access to a 
multidisciplinary team or IBD clinic, which included access to mental health treatment, IBD nurses, 
dieticians and nutritionists, an occupational therapist or exercise physiologist and for healthcare 
professionals in their team to communicate with one another. Extracts which encapsulate what the 
overarching meaning of what participants intended in the category of multidisciplinary care 
include;  
“A team that communicate with each other on a regular basis” (Participant 450, Female 
with Crohn’s, 56 years old) 
“I think incorporating other specialists such as dieticians, physiologists and GPs would 
lead to much better outcomes.” (Participant 444, Male with Ulcerative Colitis, 36 years old) 
The largest subcategory in multidisciplinary care was access to mental health support or 
treatment, accounting for just over 33% of all codes in multidisciplinary care. This sub code 
included respondents wanting to be asked about their mental health, for example; 
 “In my treatment so far, little mention or advice on the impact on mental health aspects of 
this socially isolating disease has been made…” (Participant 468, Male with Ulcerative Colitis 59 
years old) 
The sub-code also included participants wanting to have access to mental health treatment 
(psychologists, psychiatrists, counsellors and some unspecified); and wanting increased access 
(more sessions). Participants expressed that they would particularly have liked to have access to 
mental health support after diagnosis, or during flare ups;  
“…Have some mental health services offered for support and accepting diagnosis…” 
(Participant 17, Female with Crohn’s, 48 years old) 
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“Seek assistance with my mental health as the last few months during my flare up I have 
felt helpless and un worthy but I never really thought about it to be honest and it is starting to hit 
home.” (Participant 53, Female with Crohn’s, 28 years old) 
In this, participants described how the biological and social impacts of IBD had impacted 
negatively on their mental health;  
“I have a lot of fatigue and anxiety since being diagnosed and often feel that I can’t live 
my life to the fullest for my age. I think mental health needs to be considered”, (Participant 9, 
Female with Crohn’s, 31 years old) 
“Psych support in adjusting to my new lifestyle with IBD (i.e. dietary changes and the 
social impacts of this; inability to travel easily impacting former life goals etc.)” (Participant 461, 
Female with Ulcerative Colitis, 33 years old) 
Another large proportion of codes in multidisciplinary care, came from participants 
wanting access to an IBD nurse. This links to the proactive care category, as some participants 
elaborated that the IBD nurse would give them someone to talk to prior to, or instead of seeing the 
specialist;  
“I never met an IBD nurse, I think this will be a really good thing before seeing the 
specialist. Sometimes their time is taken by less important cases while the bad cases are kept 
waiting. The IBD nurse will be a really good addition to work with when you don’t really need to 
get to specialist but need to talk to someone.” (Participant 271, Female with Crohn’s, 43 years old) 
Participants wanted access to dieticians with knowledge in IBD; “…Access to Dietician 
educated in IBD”, (Participant 346, Female with Ulcerative Colitis, 65 years old)  and a small 
number of participants mentioned wanting access to occupational therapy or exercise physiology; 
“I think occupational therapy directly related to IBD should be available, and offered to all IBD 
patients on diagnosis.”(Participant 262, Female with Indeterminate Colitis, 49 years old) 
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Finally, participants expressed a wish to have different healthcare professionals 
communicate with one another, whether by interdisciplinary meetings or otherwise; “Better 
communication between GP and specialists.”  (Participant 13, Female with Crohn’s, 53 years old) 
Several participants also described problematic conflicting treatment advice from different 
professionals as a result of a lack of communication; 
 “…It’s an awkward position to be in when you have 2 gastroenterologists with different 
approaches and/or competing treatment plans/viewpoints...” (Participant 31, Female with Crohn’s, 
43 years old) 
‘Whole of person care’ 
Whole of person care accounted for 10.24% of the total codes. The title of the category 
reflects the general sentiment that participants wanted to be treated as a whole person, with 
psychosocial issues, a life outside of their IBD, and access to ‘holistic’ treatment for IBD 
(including references to complementary and alternative medicine). 
In response to the question ‘What changes would you make for your healthcare?’ 
participants described the biopsychosocial impact of their IBD; 
“…I kept saying I am in pain and experiencing persistent ongoing diahorrea 
[biological]. I was passing blood and became encontinent. My work suffered and I became a 
recluse…[social] I lived on Lomotil. I have never felt so alone I was prescribed anti-
depressants. [psychological]…” (Participant 259, Female with Indeterminate Colitis, 58 years 
old) 
The strong expressions of the biopsychosocial burden indicate that participants did not 
feel their biopsychosocial experience had been understood, recognised or considered in their 
healthcare experience. In addition to stressing the biopsychosocial impact of IBD, participants 
expressed a desire for their healthcare professionals to consider them as a whole person, with 
ancillary issues outside of their gut inflammation. This included wanting to have their pain, fatigue, 
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and weight addressed. Further, participants felt that due to their IBD, healthcare professionals 
made assumptions that all issues were related to IBD;  
“I am a long-term patient. Acknowledgement at times that not all is related to crohns 
would be good as many blame it. Being open to other issues that could be impacting my life.” 
(Participant 322, Female with Crohn’s, 39 years old) 
Participants expressed that their healthcare was currently too ‘specialised’ meaning that 
specialists failed to see other issues, and were only concerned with test results, or pathology in the 
gut;  
“…My feeling has been that the specialist doctors have blinkers on when treating their 
patients – that is, so long as the IBD is under control, they are happy …” (Participant 458, 
Female with Crohn’s, 60 years old) 
Moreover, participants wrote that specialists failed to consider the ‘big picture,’; 
“Specialists concentrate on their own field and don’t appear to consider the big picture.” 
(Participant 113, Female with Indeterminate Colitis, 75 years old) 
In this way, some participants expressed that their current healthcare failed to consider 
their quality of life, and focused too much on the biomedical aspects of IBD;  
“The emphasis was on treating my flare up rather than taking a long term view of my 
overall health and exploring all options I could undertake to improve my overall quality of 
life.” (Participant 444, Male with Ulcerative Colitis, 36 years old) 
Participants explained that they wanted their healthcare to consider lifestyle factors (i.e. 
stress, diet and exercise) as a part of their IBD management; “Specialists often say what you 
eat will not affect the condition, but I believe diet should be explored more,” (Participant 457, 
Female with Crohn’s, 46 years old), while a portion of participants described the positive 
impact changes in diet had made; “...I empower myself by managing symptoms by dietary 
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means. Unfortunately this is not a dominant paradigm in treatment options...” (Participant 2, 
Female with Crohn’s, 69 years old) 
Lastly, participants expressed wanting increased access to complementary and 
alternative treatments including marijuana. Common phrases included ‘alternative’ 
‘complementary’ ‘natural’ ‘dietary management’ ‘naturopath’ ‘alternative’ or providing a 
comparison to traditional medicine. Participants expressed they wanted their healthcare 
professionals to be more open to complementary treatments, and some participants described 
how complementary and alternative treatment assisted them to manage their IBD; 
“…I have been treating myself with complementary medicines, food and other methods 
and am doing very well…” (Participant 381, Male with Crohn’s, 58 years old) 
Whole of person care heavily overlaps with multidisciplinary care. This can be seen where 
participants describe the biopsychosocial impact, and where in multidisciplinary care they request 
access to services which can address the broader psychosocial elements of their illness. It can also 
be seen in the way participants describe wanting lifestyle factors such as diet, exercise and stress 
to be addressed, and in multidisciplinary care, participants expressed wanting access to dieticians, 
occupational therapists, and mental health treatment. 
The key distinction between ‘multidisciplinary care’ and ‘whole of person care’ was the 
specificity between the two categories. Multidisciplinary care referred to participants clearly 
expressing a desire for a multidisciplinary model of healthcare inclusive of specific healthcare 
professionals, whereas whole of person care captured participants expressing a sentiment that their 
current healthcare fails to take account of either their personalised experience, or broader 
psychosocial factors with a focus on their individual quality of life. The results contained in the 
categories of whole of person care together with multidisciplinary care, show that participants want 




Nearly 9% of the total codes came from participants expressing a desire for a more 
proactive rather than reactive healthcare. Phrases in this category included; ‘proactive care’, more 
‘routine’ and less ‘ad hoc’ care. 
“My relationships with my Drs and IBD nurse are fine but it is a reactive relationship 
rather than a proactive one…” (Participant 265, Male with Crohn’s, 63 years old) 
In some responses, participants expressed a feeling that their healthcare professionals did 
not care unless something was seriously wrong, indicating negative perceptions of acute and 
reactive healthcare experiences; 
“After severe anaemia from toxic azothioprine month long stay in hospital I realised that 
you must monitor your own health and follow up because doctors just don’t care unless something 
is wrong.” (Participant 126, Male with Crohn’s, 28 years old) 
A large proportion of codes in proactive care arose from participants articulating that they 
would like a care plan for the future, or expressing a sense of frustration at receiving assistance 
only in an acute setting without a plan for long-term management; 
“…I feel there is never a clear plan and I get stuck in hospital for days waiting for my 
symptoms to improve. I feel most things get done when I present to emergency, then when I’m 
admitted I am left with no clear plan.” (Participant 418, Female with Crohn’s 42 years old) 
 This often included a desire to have a plan in place for what the next step would be in the 
event of a flare up (including treatment options, and who to contact), as well as knowledge on how 
to monitor their own health in order to determine if hospital was necessary. In this way, a care plan 
for the future can be seen to overlap with ‘better communication’ as well as ‘multidisciplinary care’ 
given that participants wanted various healthcare professional to be involved in developing the care 
plan; 
“I think all patients with IBD should have a firm written plan of Action that they & GP, 
Specialist, & Pharmacist (and maybe Dietician) all agree to and can put into action when needed 
– The plan should have 3 major components to it 1: Normal – The day to day treatment – Drugs, 
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Dosage, & Diet 2: Flare Up (including an individualised description of what their signs of a flare 
up are) – immediate steps, medications and action 3 Emergency – When to seek emergency care 
and symptoms and instructions of what emergency symptoms are for the individual 4: All contact 
information for everyone in the Care team.” (Participant 266, Male with Crohn’s, 60 years old) 
In addition, participants expressed a desire to have more follow up, including more 
responsiveness from their IBD nurse; 
“…Follow up from doctors or nurses on discussed requirements is lacking. I have to 
constantly chase things, so improvement in that regard is needed.” (Participant 249, Male with 
Ulcerative Colitis, 47 years old) 
Consistent care and/or continuity of care contained responses which included ‘consistent’ 
‘regular’ ‘continuity of care’ or describing that they wanted to see a regular gastroenterologist at 
each visit. Some participants also described the negative impact of losing the long-term consistent 
care which they had with one doctor (i.e. due to retirement), highlighting the feelings of support 
that consistent care provided for participants;  
 “…I am feeling as though my whole support network has come crashing down and I know 
the care I had in the past is just that – in the past.”  (Participant 19, Female with Crohn’s, 63 years 
old) 
Proactive care supports the overarching results, that is participants are requesting increased 
integrated biopsychosocial healthcare. If patients are assisted to manage, adjust and understand 
their illness, through a range of multidisciplinary services, it will enable proactive management of 
IBD as ancillary issues arise, rather than reactive healthcare whereby patients only interact with 
the healthcare system during acute periods of gut inflammation.  
‘Access to treatment, services and specialist care’  
Participants wanted increased access to treatment, services and specialist care, which 
accounted for just over 16% of the total data. This also connects with proactive care, as participants 
described barriers to treatment, services and specialist care, impacting on their healthcare and 
impeding proactive management of IBD.  
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Regarding access to treatment, many participants expressed frustration at the barriers faced 
when accessing biologics; 
 “The amount of time and how hard it is to access stronger medication eg: I was 
hospitalised numerous times, lost 15kg (down to 45kg and am 5’11) within 9 months due to 30 trips 
to the bathroom per day but had to fail all drugs first (which most takes months to kick in and find 
out still aren’t working) to be able to be approved for infliximab.” (Participant 40, Female with 
Ulcerative Colitis, 28 years old) 
Participants also described lengthy weight times and a desire to have quicker access to 
support, which commonly included phrases such as “easier access to the specialist”; 
“Even with a referral I had to wait 2 months to see my Gastroenterologist after my surgery” 
(Participant 373, Female with Crohn’s, 34 years old) 
 “Access to medical support 24/7 rather than having to wait months to see specialist as 
symptoms can change quickly…” (Participant 443, Female with Crohn’s 36 years old) 
In addition, participants wanted local delivery of healthcare. This included participants 
using words like ‘closer to home’, ‘local’, and those describing having to travel to receive 
healthcare from more rural or remote areas;  
“I live rurally and have to fly to my specialist in […]. Given my symptoms this brings on 
anxiety with having to find a toilet and being stuck on a plane with the seat belt sign turned on….” 
(Participant 272, Female, Ulcerative colitis, 32 years old) 
Participants also requested more regular appointments, and this was linked in with a sense 
that infrequent and ad hoc appointments resulted in feeling unsupported; 
“Be able to see gastroenterologist more frequently…” (Participant 425, Male with 
Ulcerative colitis, 78 years old) 
“My private gastroenterologist only sees me every 3 years. I only see him the day of the 
colonoscopy, there is no consultation appointment to talk about anything else. I feel like I’m just a 
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money maker to him. I wish he was more interested in my care…” (Participant 108, Female with 
Ulcerative Colitis, 55 years old) 
 Finally, participants wanted more flexible appointment days, and access to TeleHealth 
services to reduce barriers to accessing specialist care. 
 ‘Better communication’ 
Better communication accounted for 23.5% of the total codes. Better communication 
encapsulated communications between health professionals and patients, both explicit and implicit, 
and verbal, written and non-verbal. The data indicated participants perceived information provision 
and explanation as being important to feeling cared for, and supported; 
 “More information at the beginning when I was initially diagnosed would have been good. 
I had no idea about CD and was initially given no information, so assumed it would be fixed in a 
few weeks once the medication fixed it, I did not know it was life long. I also did not know the level 
of illness I had, whether it was mild or severe. More information at all levels of care is important 
to physical and mental health. More information so patients are aware of what having IBD entails 
would be terrific. After 4 ½ years I am still learning and feel that I don’t know much about the 
disease or treatments available. I am lucky in that mine is mild so far, which may be why I was not 
given much information, but knowledge or where to get knowledge would have been a help 
emotionally so that I felt supported and so that I was not left floundering in no mans land wondering 
what was going on.” (Participant 320, Female with Crohn’s, 52 years old) 
In addition to information and explanation about IBD, medications, and treatment options, 
participants wanted to be made aware of services available to them, be given the opportunity to ask 
questions, and be provided with information that they could understand. Some participants 
described a process of information seeking, and how information and education had assisted them 
to manage their IBD; 
“I tend to manage my IBD myself through researching information such as that found on 
the Crohn’s and Colitis website” (Participant 169, Female with Ulcerative Colitis, 61 years old) 
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Participants also described a lack of empathy and understanding where their experiences 
and complaints had been dismissed, and where they had not been believed or listened to; 
“…I was fobbed off for several months, GP kept telling me I had anxiety and haemorrhoids. 
In fact I had a severely ulcerated colon and was diagnosed with Crohn’s disease…”; (Participant 
447, Female with Crohn’s, 42 years old) 
Their responses communicated a sense that healthcare professionally failed to understand 
their experience;  
“…Reminding my specialist that it is really tough living with IBD…” (Participant 419, 
Female with Crohn’s, 44 years old) 
Participants also described negative interactions where they felt they had been prescribed 
medication and sent on their way without proper care; 
“… I think specialists should have more care and follow up processes to help properly 
manage their patients, rather than to prescribe medication and send me on my way.” (Participant 
377, Female with Crohn’s, 30 years old) 
Many participants perceived that healthcare professionals did not provide person centred 
care, and had failed to see them, and communicate with them, as individuals with varying 
circumstances and experiences. They described wanting more patient choice. Frequent phrasing 
centred around doctors generalising patients, or participants emphasising the individual differences 
in IBD. As can be seen on Figure 1, this is related with ‘Whole of Person Care’. 
“doctors tend to look at blood tests then generalize patients, everyone is different and 
reacts differently ….” (Participant 122, Male with Ulcerative Colitis, 49 years old) 
“Realise we are humans not just a disease [….]” (Participant 59, Female with Ulcerative 
Colitis, 50 years old) 
Better communication also included ‘improved education and understanding of IBD for 
health care professionals’ including General Practitioners, Emergency Department staff and even 
specialists. Participants expressed a frustration that the healthcare professionals they had been in 
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contact with did not have an adequate understanding of IBD. This was coded better communication 
due to participants perceiving a lack of education and understanding undermined communication, 
understanding, diagnosis in their healthcare; 
“Some GP’s do not seem to know much about IBD. I have a j-pouch and always seem to 
have to explain what it is. Also they cannot understand why I would still need Imodium, 
Prednisolone enemas and Panadeine Forte.” (Participant 48, Female with Ulcerative Colitis, 57 
years old) 
Notably, better IBD education for healthcare professionals corresponds with ‘respectful 
care’ in the category ‘better communication.’ The following extract highlights how lack of IBD 
education was linked to participants feeling dismissed, and/or perceptions of a lack of care; 
“…I would like to see GP’s better informed about Colitis. Mine kept telling me it’s just a 
gastro bug… or perhaps it was just in my head and to focus on something else. Hard to do when 
it’s so life consuming.” (Participant 110, Female with Ulcerative Colitis, 44 years old) 
Better IBD education for healthcare professionals also links to proactive care and access to 
specialist care. Many participants expressed that if their doctors had adequate knowledge of IBD, 
they might have referred them to a specialist or diagnosed them sooner instead of dismissing their 
complaints;  
“…it took 5 years of active Crohns with recurring anal fissures, significant weight loss and 
repeated GP visits and numerous doses of antibiotics before I was finally referred to a 
gastroenterologist. More awareness by GPs and earlier diagnosis would have really been 
beneficial for me as I might have avoided surgery and psychological problems if treatment had 
started sooner.” (Participant 27, Female with Crohn’s, 66 years old) 
‘Health promotion’ 
Just over 10% of participants expressed a desire to have increase public awareness, funding, 
financial support, access to support groups as well as more research into new treatments and to find 
a cure. A small number of participants also expressed concerns or a desire to address the variability 
in healthcare services. Extracts to illustrate these categories can be found in Appendix A. The 
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participants expressed they were misunderstood by the public, with some participants expressing 
few understood the seriousness of IBD, or the difference between IBD and IBS.  
“…I’d like there to be more heightened awareness of IBD and what it means for those with 
living with it. Too often it’s confused with IBS…”  (Participant 223, Female with Ulcerative colitis, 
64 years old) 
Given that a large proportion of participants described their biopsychosocial experience of 
IBD (in the category ‘Whole of person care’), including the social impacts of IBD; it is unsurprising 
that they also expressed a desire to have increased public awareness, financial support, funding and 
access to support groups given these are all social supports. This indicates that currently healthcare 
for IBD could do more to support patients social experience of IBD. 
‘Happy with healthcare’ 
The results indicate that just under 10% of codes of the total dataset reported being happy 
with their current healthcare. Notably, approximately 16% of codes under ‘happy with healthcare’ 
category was attributed to participants being happy with multidisciplinary care;  
“I love my team! They look after me extremely well, I’m very happy.” (Participant 475, 
Female with Ulcerative Colitis, 45 years old) 
Other responses included participant stating ‘no changes’, or ‘happy with treatment’ or 
describing that they had a good relationship and were happy with a particular doctor. 
Other categories 
Improved hospital experience and administrative issues emerged as minor categories 
only accounting for 2.34% and 1% of the total data coded respectively. As can be seen in the 
diagram displayed above in Figure 1, improved hospital experience encapsulated participants 
wanting more privacy, access to their own toilet and/or room, to reduce the wait time in 
hospital. Administrative issues contained ancillary concerns which were considered to be 
separate to ‘better communication’ as defined above including; a review system for finding a 
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specialist, better record keeping, appointment reminders, reduce delays/rescheduling, to be 
given IBD clinic contact details, appointment reminders, and improved packaging for enemas. 
Discussion 
Overview and findings 
This was the first study which explored Australian IBD patient perspectives of 
healthcare. Despite there being a large body of qualitative research on the patient experience 
of living with IBD,47,48,49,50 qualitative studies on patients perspective of healthcare in IBD are 
rare.51 Previous qualitative studies have focused on healthcare professionals’ attitudes and 
perspectives.11 Other studies which have investigated patient perspectives of quality of care 
have done so using largely quantitative methods43,52 or have assessed patients from other 
countries.51 In an integrated model of healthcare, patient perspective and feedback on 
healthcare are an important tenant towards developing and maintaining optimal care.12,53 
Therefore, the current study fills an important gap in the literature; the patient perspective on 
healthcare.  
The current study found patients with IBD want multidisciplinary, proactive healthcare, 
easier access to treatment, services and specialist care and better communication with their 
healthcare professionals along with other categories. Of note, these requests directly relate to 
Australian IBD Standards of Care.12 The findings support the current standards12 as being 
relevant, but also reinforce that not only is the current healthcare falling short on objective 
quality of care measures,44 but it is also failing patients’ expectations. 
The biopsychosocial experience 
Although it is well established in the literature that IBD is a biopsychosocial illness, 
with chronic physical symptoms,54high rates of psychological distress,43,55 and negative 
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impacts on social functioning,56,57,58 the current results wherein participants have stressed the 
biopsychosocial impact of IBD indicate that patients perceive healthcare for IBD is failing to 
adequately address these biopsychosocial elements.  
Participants referenced widespread physical manifestations of IBD (i.e. fatigue, pain 
and weight), which is congruent with past literature outlining the prevalence and negative 
impact that fatigue and pain have on quality of life.59,60,61 The results also triangulate recent 
research which has highlighted high rates of psychological distress in patients with IBD43 and 
the benefits of addressing psychological factors in routine IBD care.24 These results go further 
to conclude that patients perceive their mental health to be important in their IBD healthcare 
and want access to mental health treatment in the routine care of IBD. Finally, qualitative 
research on the experience of living with IBD has outlined social factors including social 
isolation and stigma; the current study adds to this by indicating how patients would like these 
factors to be addressed in their healthcare, through increasing health promotion (i.e. public 
awareness, access to support groups and financial support).  
The multidisciplinary model of care 
In addition to describing unmet biopsychosocial needs, this study outlines that patients 
want these elements addressed by a proactive multidisciplinary model of healthcare. Previous 
research has stressed the need for multidisciplinary healthcare over biomedical healthcare in 
IBD, where the patient is only seen in times of acute illness often by a specialist doctor; 
highlighting multidisciplinary care as being more cost effective, and yielding better patient 
outcomes.15,24,16 However, this is the first study to identify that patients’ themselves perceive 




Although this study confirms prior research which identified patients want increased 
access, communication, public awareness, GP involvement, a cure and more research,51 the 
current study extends on this. Mikocka-Walus and colleagues (2018)51 were limited by a small 
sample size (n=64) and their study was conducted with participants from the United Kingdom. 
The current study focuses on Australian patients’ who exist in a different healthcare system 
and also adds to the findings, by highlighting changes in the model of healthcare delivery 
wanted. Therefore, the current results triangulate the importance of multidisciplinary care in 
Australia; not only is it more effective on objective measures and wanted by most healthcare 
professionals in Australia,11 but patients with IBD also want multidisciplinary care.  
Access to psychologists, IBD nurses and dieticians 
Distress in patients with IBD can be predicted partly by poor adjustment.62 Participants in 
the current study reflected this by highlighting that being asked about mental health or being 
provided with mental health treatment was especially wanted when diagnosed or during times 
of acute illness. In their study, Mikocka-Walus and colleagues (2019)43 (n=731) found despite 
50% of respondents experiencing distress, only 16.1% were asked about their mental health 
and only 12.2% had access to a mental health practitioner as part of their IBD care. This study 
extends these findings by outlining that participants are asking for mental health treatment as 
part of their IBD care. 
Participants also requested access to IBD trained nurses, which further cements the 
importance of IBD nurses in the IBD team as being able to provide quick advice and support,18, 
19, 20 as well as provide a point of contact between the specialist and patient.63 This study also 
extends on this by highlighting the perceived value that patients have for IBD nurses in their 
care, with IBD nurses being the second highest sub-category in multidisciplinary care. 
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Qualitative research has underscored the need for trained dieticians to be involved in IBD 
care, with results indicating participants use diet as a means to self-manage IBD, but many 
were unassisted in this by their primary healthcare professionals, and used alternative, and 
sometimes unreliable sources of information.64 The current study confirmed that while some 
participants perceived changes in diet to have helped manage IBD, others wanted access to 
dieticians. This is important given that recent study estimates that only 30% of patients with 
IBD have access to a dietician.44 Together with past research, the current results indicate that 
dieticians are needed to mitigate the risks of patients seeking unreliable dietary information to 
self-manage their IBD. 
Proactive care and access to treatment, services and specialist care 
Acute reactive management of IBD can lead to further gut damage. In addition to this, 
the current study can now conclude that Australian patients want increased, ongoing and 
regular care, follow up, and care planning for the future as part of their ongoing IBD care, not 
only during acute flares. In addition, the current study is consistent with and reinforces that 
despite IBD Standards citing patients should have specialist care within 5 days of an acute 
flare,12 not only are one-third of patients left waiting more than two weeks,44 patients are 
wanting quicker access to the specialist and reduced wait. The current study can further outline 
that patient perceptions of healthcare appear to link access to treatment, services and specialist 
care and proactive care; barriers in access are barriers to proactive care, and increased access 
to services and specialist care aid in proactive perceptions of IBD care. 
Better communication 
The current study reinforces findings from a survey conducted in the United Kingdom, 
that patients with IBD want improved communication.51 The importance of adequate doctor 
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patient communication to facilitate information and explanation about a patients’ illness has 
been highlighted in the literature across a range of chronic illnesses including 
IBD.34.36Information provision and explanation is integral to a patient being able to adjust and 
self-manage their illness.35 A hospital-based cohort study showed when participants perceived 
a lack of control over decisions regarding their treatment, they were likely to experience anxiety 
and a sense of alienation.16 Therefore, the current results add further weight to the importance 
of adequate doctor-patient communication and how it can affect the biopsychosocial elements 
of IBD; by influencing psychological elements (alienation, anxiety) and biological elements 
(self-management). In the current study this was confirmed by patients wanting increased 
patient centred care. 
Strengths 
The current study design and content analysis, allowed for both a large sample size 
which had the capacity to reflect a wider range of the views/experiences of patients with IBD 
in Australia, but also to obtain detailed and individual responses which a quantitative analysis 
would not have been able to capture. 
Limitations 
The data was obtained at the end of a larger study; therefore, participants may have 
been fatigued while they completed the responses to the open-ended question. Completion of 
the survey prior to the open-ended question (including completion of the K-10, and measures 
of disease activity) may have also primed participants to discuss biopsychosocial aspects of 
their illness. Further, participants responses could not be clarified for meaning or to resolve 
ambiguity as the researchers were not present. The current analysis had fewer participants from 
remote areas, and therefore their experiences and desires for healthcare may not be accurately 
reflected.44 Finally, the overlapping nature of the codes, means that they are not entirely 
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distinct, and the nature of content analysis means the count of codes may be biased by some 
participants repeating certain codes multiple times.46 However, the overlapping nature reflects 
multidisciplinary models of care and the interactive biopsychosocial elements of IBD.  
Implications for future research 
Despite IBD standards, and research advocating for proactive multidisciplinary 
healthcare, it is lacking and wanted from patients. Given that research suggests most healthcare 
professionals in Australia have endorsed multidisciplinary care for IBD11 future research could 
investigate what current barriers remain in the implementations of biopsychosocial healthcare 
in Australia. In line with this, the current results did not elucidate the higher-level organisation 
and management of the healthcare system. Future research could examine what organisational 
changes are needed to facilitate patients access to integrated multidisciplinary healthcare 
services, to aid in reducing wait times, and facilitating access to a broader range of treatment 
options. Finally, future research could explore if there are key differences between IBD patients 
experiencing acute flares, in remission or other variables that influence desired healthcare.  
Concluding remarks and implications for healthcare 
Healthcare professionals should focus on improving communication, and increasing 
information provision and explanation, as well as increasing interdisciplinary communication. 
Communicating in patient-centred terms so that patients are heard understood and have a 
choice in their treatment should also be a priority. Patient’s should be asked about their mental 
health, particularly during acute illness, or during diagnosis. Facilitating patients’ access to 
multidisciplinary services (i.e. psychologists, dieticians and IBD nurses) should also be a 
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Appendix A – Demographics 
Table 1   
Demographics  
Age 
17-84 (Average 48) 
Gender 
73% female, 26.8% male, 0.2% other 
IBD type 
UC: 41.1%, CD 55.8%, Indeterminate colitis: 3.1% 
Remoteness 
Inner Regional: 22.2%, Major Cities: 70.6%, Outer 
regional: 5.9%, Remote:1%, Very remote: 0 
Education 
12.5% less than year 12, 36.5% Bachelor’s degree. 
17.0% vocational education (TAFE), 15.3% year 12, 
10.3% Master’s degree, 2.5% PhD, 5.9% other 
Marital status 
66% married/de facto 






Employed full-time 30.4% 
Unemployed/looking for work 23.3%, unemployed/not 
looking for work 1.9% 
Student 6.7% 







Appendix B – Table with content analysis coding structure (categories, sub-codes and extracts) 
 
Table 1 
Category: Multidisciplinary care 













Access to mental health 
treatment n=61 
To be asked about mental health 
 
More access to mental health 
 
Access to mental health 
“More conversation around mental health – 9/10 you’ll say I’m fine even if you’re 
not…” 
“Longer access to mental health plans” 
 
“Access to therapist to discuss the disease…” 
 
Access to IBD nurse n=42 Access to IBD nurse 
 
IBD nurse helped  
 
“I never met an IBD nurse, I think this will be a really good thing before seeing 
the specialist…” 
 
“…the nurses on the other hand have been caring and extremely involving in 
everything we do.” 
 









Reduce conflicting treatment 
advice 
 
Interdisciplinary meetings have 
improved care 
“Better communication between the GP and the specialists” 
 
 
“It’s an awkward position to be in when you have 2 gastroenterologists with 
different approaches…” 
 
“I found I have had better care…where they meet regularly with other 
gastroenterologists and colorectal surgeons to discuss different cases…” 
 
A team n=24 
 
N/A “Dedicated team comprising of dietician, nurses and physiologist” 
IBD clinic n=6 N/A “I would like access to an IBD specialist unit of some kind, I have never been 
offered anything other than my consultations…” 
Nutritionist n=4 Want access to nutritionist 
Nutritionist helped 
“…Nutritionist would be good as well” 




N/A “I think occupational therapy directly related to IBD should be available, and 
offered to all IBD patients on diagnosis” 
Specialist to value MD 
services n=1 
N/A “Encourage gastro’s to recognize the value of complementary treatments from 






Category: Better communication  




















on n=92  




“Early information and education. When I was diagnosed, no one spoke 
to me about the seriousness of UC, what can happen I ended up nearly 
dying and waking with an ileostomy during my second flare EVER” 
More information provided about 
medication side effects (including 
having long term effect of 
medications discussed) 
 
“more information on drugs and side effects” 
 
More written information  
 




“The internet has thrown me a lifeline with many forums on the topic” 
To be made aware of services 
available 
 
“Told about options and what I have access to. I don’t feel I have any 
support at all” 
Easy to understand information  
 
“Easy to understand answers” 
 
To be able to ask questions 
 
“Feel it’s difficult at times to ask questions.” 
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Information about treatment 
options 
 




“I think more studies and information for people pregnant living with 
IBD” 
Respectful care n=57 To be believed 
“At one stage the GP said it was all in my head?” 
To be heard and understood 
 
“Listening to the patient more rather basing treatment off tests alone” 
More understanding/empathy  
 
I don’t feel important or valued. Just a number. When I show concerns 
about my multiple meds and the possibility of reducing them now that 
I’m in remission I feel like its all too hard. Possibly just easier for the 
specialist to continue the same” 
To be informed about own 
treatment 
 
“As surgeons haven’t told me what the outcome of either of my bowel 
ops would be I was worried when I still had diarrhea etc. Liaison 
between the gastro and surgeon AND patient. I was told nothing about 
what to expect after my first bowel op.” 
Don’t want to be told ‘take these 
meds’ and sent away 
 
“I think specialists should have more care and a follow up process to 
help properly manage their patients, rather then to prescribe medication 
and send me on my way” 
90 
 
For doctor to ask more questions 
 
though he does leave it up to me to ask the questions and ask for the 
referral to my Gastroenterologist” 
Not to be dismissed 
 
I hate being dismissed as I don’t know anything and they the doctors are 
superior and not to be questioned” 
To be treated with respect 
 
“Often I have been dismissed and treated with disrespect in the 
emergency department. I feel they do not resonate with us” 
 
Not to be kicked out of ED “…they’re so eager to kick you out as quickly as possible afterwards” 









Better education for healthcare 
professionals generally  
“GP’s need to research IBD and realise the effect it has on your life” 
 
 
“The emergency department healthcare system. They need to be 
educated about IBD….” 
 
“more IBD education generally and hopefully this will lead to more 
empathy for patients who present with this disease …” 






“I prefer my IBD doctor to give more time to explain to me and help find 
















“Infusion centre staff need better support. They are always short staffed 
and this is grossly unfair to them and patients” “ 
 
“…He forgot I’d had the IBD check before starting Humira and suggested 
again I did the test. When I told him I already had, he admitted the 
application forms for Humira must be sitting in his desk & had been there 
for a while, all the while I had been on pred for months and struggling 
along. Humira failed and now I’m on remicade but he keeps forgetting 




N/A “Face to face contact could be improved. Particularly with specialists” 
 
OR specific example 
 
“Unfortunately, I had very negative experiences with my original 
Gastro who would tell me I was ‘very lucky, many people are worse 
than me!’ When you are 18 and having to continually rush the toilet, 




Person centred care 
n=24 
N/A “better one on one care more personal attention” 
At diagnosis/in ED 
n=5 
N/A “I would change the way my initial diagnosis was made. After a 
colonoscopy without a suspected Crohn’s, I was told quite abruptly that 
I had crohn’s disease straight after the colonoscopy. I was told I needed 
to immediately take budenofalt (steroid) and immunosuppressants and 
I’d be on medication for the rest of my life. This was too much to take in, 
straight after a colonoscopy and without any forewarning. Because of 
this I changed gastroenterologists and saw a private specialist form the 
same clinic” 
Doctor to be more 
involved n=5 


















Table 3  
Category: Access to treatment, services and specialist care 


















Treatment options or 
access to medications 
n=61   
Access new treatments or drugs (more 
treatment options, drug trials and 
alternative to steroids) 
 
Reduce regulatory restrictions on 
biologics 
 
Medication management (i.e. new 
meds, improved management of scripts) 
 
Reduce immunosuppressant use 
 
 
Treatment for perianal disease 
“I would like access to trials for new treatments…” 
 
 
“I hate that there is such a time delay when changing drugs. When 
you are really sick and you have to wait for approcal of new drugs 
(ie biologica) it cuses more stress and pain…” 
 
 
“More support when ringing up for scripts or help..” 
 
“Find a way to reduce dependency on Meseal” 
 
 
“Would like more help with perianal disease…” 
Reduce wait times 
n=40 
Wait times 
Quick access to support 
Telephone advice 
 
“Waiting times for the specialist…” 
“Access to medical support 24/7” 
“A phone help line…” 
Easier access to 
specialist care n=38 
Easier access generally 
 
Easier way to contact specialist 
 
GP to provide specialist referral sooner 
 
“Easier access to specialists” 
 
“To make contacting Gastroenterologist easier…” 
“…It took me 1 month of seeing 5 doctors in the ACT before I was 
sent to a specialist..” 




Access to private GI 
 
More specialist colonoscopies 
 
Access to fistula repair surgery 
Fecal transplant  
 
Frequent colonoscopy 
Ileal pouch surgery  
 
 
“I want to get Fistula Repair surgery done…” 
 
“sincerely wish that Fecal transplants were more easily accessible 
in hospital environment…” 
 
“Maybe have a colonoscopy once every 12 months rather than the 
current 24 months” 
 
“Ileal pouch surgery – colorectal surgeons don’t do the procedure 
often enough…” 
Local delivery of 
healthcare (rural and 
remote access) n=35 




N/A “More regular specialist visits every 6 months is way too long a lot 
can happen in 6 months” 
Flexibility of 
appointment days, 
IBD clinic open more 
days n=4 
N/A “…I would like choice of our patient clinics. The one I was 
attending was evening only, and very difficult to attend..” 
Access to TeleHealth 
services n=3 
N/A “…even be able to have follow up appointments with my ibd team 










Category: Whole of person care  





















Burden of ongoing healthcare 
 
Psychosocial changes helped 
 
 
Want psychosocial changes 
“…The cost both financial and emotional adds to the stress of 
managing complex and chronic disease” 
“…It becomes so hard to manage and juggle all of these appts and 
tests.” 
…without the stress of being at work…I have been able to manage my 
bowel symptoms much better..” 
 
“Changing my employment so have less stress” 
 
Lifestyle factors Lifestyle changes (diet, stress and 
exercise) 
Diet helped 
“…I can manage the symptoms through diet and stress reduction 
however, they do not see this as a legitimate alternative to medication 
even though I experience it and know that it works for me” 
“…My diet and avoiding some food has increased my quality of 
life…” 
CAM’s CAM’s (alternative) 
Marijuana  
CAM’s helped 
Doctors to be more open to CAM’s 
“…I think using alternative meds should be suggested…” 
“Access to medicinal marijuana products” 
“…Since seeing a naturopath ….I am finally managing my disease” 
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“…there is a lack of respect between traditional health care and 
alternative…” 
Holistic care N/A “A holistic approach…” 
Pain management N/A “…That my Gastroenterologist acknowledged and treated my pain, 
and that my concerns about pain weren’t dismissed…” 
Address other health 
issues 
Including muscle dysfunction and 
rectoceale  
“…I would like to be seen as a whole person with other possible 
issues (eg I have fibromyalgia/connective tissue disease and a DVT 




N/A “…One observation I have is all gastroenterologists focus almost 
exclusively on prescription drugs…” 
Quality of life N/A “…not looking at the whole person or quality of life” 
Weight management N/A “…I just feel I may need a little more assistance with weight gain 
issues” 
Family involvement N/A “…Sharing info with people in my life so they understand” 
Fatigue N/A “…However I am discharged from surgical and my 
gastroenterologists do not ask about fatigue and when I mention it I 
am dismissed as my illness essentially is no longer…” 
Gut bacteria testing 
n=1 
N/A “maybe even gut bacteria testing incase we don’t have the right ones 






Category: Health promotion  














Access to public toilets 
 
More workplace support 
“More public awareness and understanding…” 
“It can be difficult to find bathrooms quickly. If more people were 
aware of how embarrassing ibd can be then there would be more 
public facilities available…” 
“…Workplaces to be more understanding of IBD, and other related 
symptoms such as fatigue” 
Financial support 
n=25 
Decreased cost of medication  
Access to healthcare card/Centrelink 
“More access to reduced price medication and services…” 
“…more support from Centrelink and access to disability” 
Support groups n=24  Support groups 
 
 
Access to ACCA helped 
 
Support groups helped 
“…more support groups to talk to other people to see what others are 
going through…” 
 
“Make sure all new patients are encouraged to access ACCA”  
 
“…I’m very grateful to be part of such a wonderful group.” 
 
Research n=21 Research  
Dissemination of research  
 
“…I hope more research can be done to figure out this baffling 
disease 
“Be kept informed of the latest research…” 
A cure n=10 N/A “…I don’t want to manage IBD, I want a cure” 
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Funding n=6 N/A “Funding for care and medications -very expensive…” 





Category: Proactive care 















Care plan n=28 Care plan 
 
Participant expressing concern for 
future 
“A care plan and strategies for flare ups” 
“I have a mild case of Colitis and am concerned that this may get 
worse as I get older and I don’t really know what to do to help with 
this” 
Consistent 




“try and have a regular team of people to support you, familiar 
faces are important…” 
Follow up n=15 N/A “…In all cases of seeing a specialist – I have never had any support 
or follow up and think this is something that is very important…” 
Proactive/preventative 
care/regular care n=12 
N/A “…Currently if the patient is well specialists provide 5-10 mins with 
no or little feedback” 
Earlier diagnosis n=10 N/A “To get that early diagnosis is key! You know your own body better 
than anyone else. Get that second or even third medical opinion if 








N/A “…often the IBD nurse never gets back to me when I call, and 
rarely answers my calls” 
Avoid hospitalization 
n=3  
N/A “….to avoid the emergency department” 
Regular blood tests 
n=3 
N/A “I have irregular blood tests which concerns me greatly as I’d like 




N/A “I would like to see surgery discussed earlier on in treatment of 
IBD…” 
Connected to the 
clinic sooner n-1 
N/A “…Would have liked to be connected to them [IBD clinic] sooner, 




Category: Happy with healthcare 








Happy with treatmen 
n=51t 
N/A “I wouldn’t change anything everything has been really well” 
No changes/nil n=26 N/A “None” 
Happy with MD care 
n=18 
N/A “At present I have a good team looking after me” 
Happy with doctor 
n=17 





Category: Administrative issues 




















Fewer regulatory restructions  
hould not need continuing referrals 
Want recurring colonoscopy without 
administration  
Not having to visit GP for blood test 
forms 
“More understanding from regulators that out diseases do not 
always fit into neat boxes…” 
“…I think with a long term chronic illness referrals should not be 
necessary” 
“Having scheduled colonoscopy on an annual basis without having 
to go through the gp/specialist…” 
“Not having to visit the GP to get blood test forms…” 





“We need a forum/review system for Gastroenterologist and other 
specialists so we can find a good one” 
Record keeping n=6 N/A “Better note taking systems so I’m not repeating myself over and 
over” 
Reduce delays or 
rescheduling n=2 
N/A “…finding out that they have exams and need to be rescheduled two 
weeks before is really awful…” 
Confirmed contact 
details for IBD clinic 
n=2 
N/A “Having confirmed contact details for the ibd clinic…” 
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GI to automatically 
arrange meeitngs n=1 
N/A “…gastroenterologist to automatically arrange meetings for me like 
the hospital does…” 
Message to remind for 
appointments n=1 
N/A “A message to remind you of upcoming appointments, I have found 
my memory is significantly worse than it was…” 
Packaging for enemas 
n=1 
N/A “Well it’s a simple thing, but the packaging used for steroid enemas 




Category: Improve hospital experience and patient comfort 











Access to own toilet 




“…I felt there wasn’t adequate access to toilet facilities. I was 
having to open up my bowels up to 15 times a day and in almost all 
cases with urgency…” 
More privacy n=2  
N/A 
“More consideration when going to public hospital for Flexi sig. 
they administer an enema with just the curtain (very little 
privacy)…” 
Reduce time in 
waiting room n=2 
N/A “I was left in the waiting room for 4 hours…” 
A clean ward to sit in 
n=1 










Better powder drink 
prior to colonoscopy 
n=1 
N/A “…Invent a new Bowell prep tablet for prior to colonoscopy, the 
existing powder drink is dreadful and difficult to drink…” 
Gentler preparation 
for colonoscopy n=1 
N/A “Each reaction to the colonoscopy preparation gets worse to the 
extent that I never want to have one again – even at the risk of 
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Based on the information provided, the editors will determine whether COI exists and decide to either a) 
reject the manuscript or b) publish the manuscript with the COI disclosed. 
 
c. Reviewers: When invited, reviewers must decline to review a manuscript if a potential COI exists. After 
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b. Duplicate Submission/Publication: Occurs when two or more papers, without full cross-reference, share the 




Should plagiarism or duplicate submission/publication be identified, the journal editors will apply the following 
sanctions according to the severity of the infraction. They will apply sanctions to individual authors depending on their 
type of involvement with the article, as provided at the time of submission on the title page. 
a. A letter of explanation from the journal editors to the authors where there appears to be a genuine 
misunderstanding of principles. 
 
b. A letter of reprimand from the journal editors as to future conduct. 
 
c. A formal letter from the journal editors to the author's institution, employer, or funding body. 
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be made explicit by the arrangement of the figure (e.g., using dividing lines) and in the text of the figure 
legend. 
c. Adjustments of brightness, contrast or color balance are acceptable if they are applied to every pixel in the 
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figure legend. 




The journals' graphics staff will screen images at random during the submission process and will review images that 
editors, reviewers or readers suspect have been manipulated. If manipulation is suspected, the staff and editors will 
initiate an investigation with the authors and possibly their institutions. 
 
C. Sanctions 
Should image manipulation be verified before or after publication of an article, one of the below sanctions will be 
applied, based on the severity of the infraction. The journal editor-in-chief and board of editors will determine, on a 
case-by-case basis, the severity of the infraction and corresponding sanction. Sanctions will be applied to individual 
authors depending on their type of involvement with the article, as provided at the time of submission on the title page. 
a. A letter of explanation from the journal editors to the authors where there appears to be a genuine 
misunderstanding of principles. 
b. A letter of reprimand from the journal editors as to future conduct. 
c. A formal letter from the journal editors to the author's institution or employer. 
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OPEN ACCESS POLICIES 
 
Compliance With Funders' Open Access Policies 
CGH's publishing partner, Elsevier, has established agreements and developed policies to allow authors who publish in 
Elsevier journals to comply with manuscript archiving requirements of various funding bodies (for example, the 
National Institutes of Health), as specified as conditions of researcher grant awards. For a full list of funding bodies with 
which Elsevier has agreements, go to https://www.elsevier.com/about/publishing-guidelines/policies/funding-body-
agreements. These agreements and policies enable authors to comply with their funding body's archiving policy 
without having to violate their publishing agreements with CGH. The agreements and policies are intended to support 
the needs of the Journal's authors, editors, and society publishing partners, and to protect the quality and integrity of 
the peer-review process. 
 
Author-Sponsored Articles 
CGH offers authors the option to sponsor immediate open access to their articles online 
at www.cghjournal.org and www.sciencedirect.com. Authors can elect to sponsor their article only after receiving 
notification that their article has been accepted for publication in CGH. The charge for article sponsorship is $3000, 
which is used to offset publishing costs of typesetting, tagging, and indexing of articles, hosting articles on dedicated 
servers, supporting sales and marketing costs to ensure global dissemination via www. 
cghjournal.org and www.sciencedirect.com, and permanently preserving the published journal article. The fee excludes 
taxes and other potential author fees such as submission, page fee, and color charges, which are additional. Authors who 
have had their article accepted and who wish to sponsor their article to make it immediately freely available should 
complete and submit the sponsored article order form. You will need your Elsevier Production Article Number to 
complete the form. You will receive this number via email once your accepted manuscript has been received and 
processed by the Elsevier team. 
 
Open Issue Highlights and Archives 
AGA supports free access to CGH on the broadest possible basis while adhering to a publishing model that is 
economically sustainable over a long horizon. To that end, for each issue of the Journal, several original research 
articles are identified by the Journal's editor as critical content for readers and thus are made immediately open access. 
Additionally, all content older than 12 months is free to all online. Also, many special sections of each new issue are 
immediately free to all online. 
 
Manuscript Posting 
Authors of articles published in CGH may voluntarily post their accepted manuscripts to personal websites or 
institutional repositories immediately upon acceptance. 
 
INFORMATION ABOUT ARTICLE TYPES 
 
Original Articles 
Original Articles are full-length reports of original research and will be considered for either the Alimentary Tract or 
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Pancreas, Biliary Tract, and Liver sections of the Journal. Articles cover topics relevant to clinical studies in these areas 
of interest. They may discuss nutrition, morphology, physiology, pathophysiology, epidemiology, imaging, or therapy. 
Both adult and pediatric problems are included. To be published, the work presented in the manuscript must be 
original; on occasion, confirmatory studies of timely and important observations will also be acceptable. In addition, 
other considerations for evaluating the acceptability of a submitted manuscript include its importance, the soundness of 
the experimental design, the validity of the methods, the appropriateness of the conclusions, and the quality of 
presentation. 
 
Original articles submitted to CGH cannot exceed 4,000 words including the figure and table legends, and references. 
No more than six figures and/or tables are permitted, though more may be included online as supplemental material. 
Each figure may have up to six panels (labeled A-F). The editor reserves the right to publish excessively long tables as 
online-only material. Your manuscript will be returned to you if it does not meet these criteria. 
• Manuscript: only Microsoft Word documents will be accepted. 
• Title page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest 
statement (for all authors). 
• Word count: 4,000 words (inclusive of main text; references; table/figure legends). 
• Abstract: 260 words, structured as follows: background and aims; methods; results; conclusion; 4-5 keywords. 
• Tables/Figures: 6 tables (no panels) and/or figures (up to 6 panels) total. 
• Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution). 
• Randomized Controlled Trials: Provide CONSORT checklist and patient flowchart as supplemental attachments. 
• Clinical Trials: 
• Provide the clinical trial registry website and trial number at the end of the "conclusions" section of the abstract. 
• Include a statement in the "methods" section of the manuscript affirming that "all authors had access to the study 
data and reviewed and approved the final manuscript. 
• Include the clinical trial protocol in English as a supplemental attachment. 
• Revised manuscripts: 
• References: please list names of authors who share first authorship in bold text. In addition, include the phrase 
"Author names in bold designate shared co-first authorship" at the end of the references section. 
• What You Need to Know: This note will appear as a box on the second page of the published version of each article, 
containing summarizations about your study under the following 3 headings: BACKGROUND, FINDINGS, 
IMPLICATIONS FOR PATIENT CARE. Please provide 25-30 words under each of these 3 headings that very 
briefly summarize your study in relation to each category. 
 
 
Narrative Reviews Invited Only) 
Narrative Reviews are invited reviews from experts in the field on a particular topic of interest to the CGH readership. 
These reviews are typically 6,000 words (references are included in this word count) in length and include a maximum 




Systematic Reviews and Meta-analyses 
Systematic Reviews and Meta-analyses are solicited and unsolicited manuscripts that feature an organized and detailed 
review of the scientific literature about a particular topic. This section is peer-reviewed and acceptance for publication 
is not guaranteed. The length must not exceed 6,000 words (references are included in this word count) and a 
maximum combination of six tables and/or figures can be included. For meta-analyses of randomized, controlled trials, 
authors must provide a CONSORT checklist at manuscript submission and follow the PRISMA reporting guidelines 
found here: http://prisma-statement.org/. For meta-analyses of observational studies, authors must follow the MOOSE 
reporting guidelines found here: http://www.editorialmanager.com/jognn/account/MOOSE.pdf. Your manuscript will 
be returned to you if it does not meet these criteria. 
• Manuscript: only Microsoft Word documents will be accepted. 
• Title page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest 
statement (for all authors). 
• Word count: 6,000 words (inclusive of main text, references, and table/figure legends). 
• Abstract: 260 words, structured as follows: background and aims; methods; results; conclusion; 4-5 keywords. 
• Tables/Figures: 6 tables (no panels) and/or figures (up to 6 panels) total. 
• Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution). 
• Randomized Controlled Trials: Provide CONSORT checklist as a supplemental attachment. 
• Revised manuscripts: 
• References: please list names of authors who share first authorship in bold text. In addition, include the phrase 
"Author names in bold designate shared co-first authorship" at the end of the references section. 
• What You Need to Know: This note will appear as a box on the second page of the published version of each article, 
containing summarizations about your study under the following 3 headings: BACKGROUND, FINDINGS, 
IMPLICATIONS FOR PATIENT CARE. Please provide 25-30 words under each of these 3 headings that very 
briefly summarize your study in relation to each category. 
 
 
Image of the Month 
Image of the Month presents a striking clinical image(s) that is meant to challenge and inform the reader. Although 
priority will be given to exceptionally unique submissions, and those that are not similar to recently published cases; 
authors should be encouraged to present quality images of more commonly encountered diseases and conditions. 
 
All submissions will be considered for both print and online-only publication. Any Image of the Month submissions 
that contains video alone will be limited to electronic publication only. Authors of Image of the Month submissions are 
not required to pay for color image reproduction. All submissions should contain no more than four (4) color or black 
and white images of 300 DPI resolution. Images should be accompanied by a Word document containing a brief 
description of no more than 200 words with no abstract, figure legends, or references. Submissions should not have 
more than 3 authors. The text should succinctly present relevant clinical information, including a short description of 
the patient's history, relevant findings, clinical course, response to treatment, and condition at last follow-up. 
Endoscopy images should be free of lettering, words, or numbering and associated pathology images should be included 
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when appropriate. Image of the Month articles are indexed on PubMed. Your manuscript will be returned to you if it 
does not meet these criteria. 
• Manuscript: only Microsoft Word documents will be accepted. 
• Title page: title; authors' names (limit of 3); authors' institutions; corresponding author contact information; conflict 
of interest statement (for all authors). 
• Title should be declarative and succinct. Editors may modify the title according to journal style. 
• Word count: 200 words. 
• Abstract: No abstract. 
• References: No references. 
• Figures: 4 figures (no panels) total. No figure legends/image captions, all pertinent information must be included in 
main text. 
• Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution). 
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Letters to the Editor 
Letters to the Editor offer opinions on papers published in CGH. Such correspondence is evaluated only for articles 
published within one month of submission of the letter (eg, for the January 2020 issue, letters submitted after February 
29, 2020 will not be considered). Those letters deemed of interest to the Journal (typically less than 25% of those 
submitted) are sent to the authors of the original article for a response; the authors are given 2 weeks to reply. A 
decision will then be made whether to publish the letter with or without its reply. 
 
Letter to the Editor submissions must not exceed 750 words, with no more than 8 references (not included in the word 
count). Original or unpublished data will not be considered. For the references, use the following format: Jones RS, et 
al. Clin Gastroenterol and Hepatol 2011; 2: 373 -380 (only first author is listed and article title is not included). The 
correspondence and the reply cannot include more than 3 authors each. All letters become the property of CGH and are 
subject to editing by the Journal. Letters are selected based on their relevance and originality. CGH will not publish 
letters commenting on manuscripts for which letters have already been published. Your manuscript will be returned to 
you if it does not meet these criteria. 
• Manuscript: Only Microsoft Word documents will be accepted. 
• Title Page: title; authors' names (limit of 3); authors' institutions; corresponding author contact information; 
conflict of interest statement (for all authors). 
• Word Count: 750 (includes main text only). 
• Abstract: No abstract. 
• Tables/Figures: Not permitted. 
• References: Limited to 8. 
• Format: Jones RS, et al. Gastroenterology 2011;2:373-380 (only the first author is listed, unless manuscripts with 
joint first authors are cited, and article title is not included). 
• Must reference an article in press or an article appearing in the current issue at time of submission. (e.g., a response 






Research Correspondence are concise and smaller scientific reports of original research studies. The format is as follows: 
no abstract, article text must not exceed 750 words (not including table, figure, or references) and 8 references and may 
include up to 1 table or figure. If needed, these may include 1-2 additional figures or tables as supplementary material, 
for describing results, and up to an additional 500 words of text for describing methods. The text cannot be used to 
provide additional results or discussion. These reports are not the same as a Letter to the Editor and must not duplicate 
other material published or submitted for publication. Research correspondence must be divided into the following 
sections: Introduction, Methods, Results, and Discussion, and all article titles should be declarative. Your manuscript 
will be returned to you if it does not meet these criteria. 
• Manuscript: Only Microsoft Word documents will be accepted. 
• Must be divided into following sections: Introduction, Methods, Results, and Discussion. 
• Title Page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest 
statement (for all authors). 
• Word Count: 750 words (includes main text only). 
• 500 additional words of text for describing methods may be included as supplementary material. 
• Abstract: No abstract. 
• Tables/Figures/Videos: May include up to 1 table (no panels), figure (up to 6 panels), or video. 
• 1-2 additional figures or tables for describing results may be included as supplemental material. 
• Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution). 
• References: Limited to 8. 
• Format: Jones RS, et al. Gastroenterology 2011; 2: 373-380 (only the first author is listed, unless manuscripts with 
joint first authors are cited, and article title is not included). 
• These reports are not the same as a Letter to the Editor and must not duplicate other material published or 
submitted for publication. 
 
 
Continuing Medical Education (CME) 
Selected issues of CGH will contain continuing medical education exams associated with articles that appear in the 
issue. AGA members can take the exams online free of charge. Non-AGA members are required to pay a $15 processing 
fee. Readers can claim 1.0 AMA PRA Category 1 Credit™ and 1 Maintenance of Certification (MOC) credit. Physicians 
should claim only the credit commensurate with the extent of their participation in the activity. 
 
 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the 
participant to earn up to 1 MOC point in the American Board of Internal Medicine's (ABIM) MOC program. 
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the AGA's 







All manuscripts should be typed in 12-point font size and double-spaced and should contain the following sections in 
the order given below. All manuscripts submitted to CGH are made available for online review. Authors should submit 
their manuscripts, with figures and tables, electronically via our website, http://www.editorialmanager.com/cgh . 
Complete instructions for online submission are located on the website. 
 
Cover Letter 
CGH strongly encourages authors to suggest three to four referees (include their e-mail address, phone, and fax 
numbers) and the Associate Editor they believe best qualified to review their paper. Authors may also list a non-
preferred Associate Editor and non-preferred referees, but the ultimate selection of an Associate Editor and referees is 
at the sole discretion of the Editor and Associate Editor, respectively. A list of our current Associate Editors can be 
found at http://www.cghjournal.org/content/board-of-editors. 
State reasons for deviations, if any, from standard format and clarify any potential conflicts related to the exclusive 
nature of the publication. The cover letter must also categorize the manuscript into one of two groups: Alimentary 
Tract or Pancreas, Biliary Tract, and Liver. 
 
Title Page 
Title--Use no abbreviations. Limit: 120 characters including spaces. Must state the main finding of the study. 
Short Title--Limit: 45 characters with spaces. 
Authors--Include first names of all authors and name and full location of department and institution where work was 
performed. 
Grant Support--List grant support and other assistance. 
Abbreviations--List abbreviations alphabetically. (Note: In general, the use of abbreviations is discouraged.) 
Correspondence--Provide name, complete address, e-mail address, and telephone number of corresponding author. 
Disclosures--All authors must disclose any potential conflicts (financial, professional, or personal) that are relevant to 
the manuscript. If the author(s) has nothing to disclose, this must be stated. 
Preprint server--If your manuscript is posted to a preprint server, you must indicate as such on the title page and 
include the DOI of the preprint. 
Writing Assistance--The names and funding source for individuals who provided writing assistance must be listed. 
Author Contributions--This information no longer needs to be included on the Title Page. Instead, the Corresponding 
Author will select from a list of roles for each co-author from CRediT Taxonomy. Detailed instructions can be found at 
https://www.editorialmanager.com/cgh when submitting a manuscript. 
 
Corresponding Author Duties: 
 
When submitting a manuscript, the Corresponding Author needs to contribute the following: 
• Have an active account on editorialmanager.com/cgh with a current email address. 
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• Submit the manuscript with all of the steps. 
• List a current email address for all co-authors, so they can confirm their roles and co-authorship for the paper. 





Abbreviations must be spelled out at least once. Do not use footnotes or references. Structured abstracts should be 260 
words or less and include the following sections: 
 
Background & Aims: Provide one-to-two sentences of background information to indicate why the study is interesting 
and important. Provide one sentence to state the main question addressed by the article. 
 
Methods: Methods should include information on the following aspects of study design, when applicable. 
• Design--describe the basic study design, e.g., randomized controlled trial, cross sectional study, cohort study, case 
series, survey, etc. 
• Setting--specify whether the study was conducted in a primary or tertiary care setting, in an ambulatory care clinic 
or hospital, in the general community, etc. 
• Participants--indicate the number of study subjects, how they were selected, what key features were included. 
What data were collected? 
• Intervention--report the method of administration and duration of the intervention. Describe control groups and 
what methods were used to analyze the data. 
• Describe main outcome measures. 
 
For studies that are quality improvement (QI) related, authors must include a statement about IRB review. Authors 
must include one of the two statements: 1) This study received IRB approval, and include protocol number; or 2) This 
study was exempt from IRB review after institutional IRB review. 
 
Results: Describe the main findings of the study, including confidence intervals or P values. Report the absolute values 
and risk differences so that readers can determine the absolute, as well as the relative, impact of the results. Please be 
consistent in reporting either number or percentage values. 
 
Conclusions: State conclusions that are directly supported by the evidence and the implications of the findings. For 
clinical trials, state the clinical trial registration web site and number (e.g., ClinicalTrials.gov, Number NCT002209456). 
 
Keywords 
Include three-to-four keywords associated with your manuscript, separated by semicolons (e.g., active vitamin D; 




The keywords should be terms not already included in the title or abstract. Should your manuscript be accepted, the 
keywords will appear with the published manuscript, making it easier to find in literature search engines such as 
PubMed. 
 
What You Need to Know 
All revised original research submissions (including Alimentary Tract articles; Pancreas, Biliary Tract, and Liver 
articles; and Systematic Reviews and Meta-analyses) must include text for a "What You Need to Know" box to appear 
on the second page of the published article. The text should include and relate to the following three headings: 
• Background 
• Findings 
• Implications for patient care 
 
Please provide 1-2 sentences (25-30 words) under each of these three headings that succinctly summarize your study in 
relation to each category. This text should not include nonstandard abbreviations. Please upload this content in a single 
Word document file, separate from other manuscript materials. 
 
Body of paper 
Describe ethical guidelines followed; cite approval of institutional human research review committee or animal welfare 
committee; describe in detail hazardous procedures or chemicals involved, including precautions observed. 
 
Outline statistical methods used. 
 
Identify drugs and chemicals used by generic name (if trademarks are mentioned, manufacturer name and city are 
given). 
 
All gene and protein names must be written according to NCBI or HUGO nomenclature. Official NCBI gene full names 
and symbols are preferred, although "Other Aliases" will be accepted. The Editors acknowledge that exceptions to these 
guidelines exist, and these will be considered on a case-by-case basis. 
 
References 
Cite references in order of appearance in text using superscripted Arabic numerals. Cite personal communications and 
unpublished data directly in text without being numbered. All abbreviations should follow the Index 
Medicus abbreviations. 
 
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and 
including a data reference in your Reference List. Data references should include the following elements: author 
name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] 
immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not 




Article (list 3 authors followed by et al): 




18. Day RA. How to write and publish a scientific paper. Philadelphia: Institute for Scientific Information, 1979. 
 
Article in Book: 
22. Costa M, Furness JB, Llewellyn-Smith IF. Histochemistry of the enteric nervous system. In: Johnson LR, ed. 
Physiology of the gastrointestinal tract. Volume 1. 2nd ed. New York: Raven, 1987:1-40. 
 
Dataset: 
5. Oguro M, Imahiro S, Saito S, et al. Mortality data for Japanese oak wilt disease and surrounding forest compositions, 
Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/xwj98nb39r.1. 
 
Tables 
Tables should be prepared without the use of tabs; most table editor programs can be uploaded successfully. If your 
table contains decimal fractions, please round your numbers to two places after the decimal point. Tables may be 
embedded in the file that contains your manuscript or attached as separate files. Please spell out all abbreviations used 
in the table in an accompanying footnote. 
 
Figures 
For additional information regarding journal guidelines for figure submissions, please see our Figure 
Submission FAQs. 
 
Images: Images can be clinical, pathologic (gross or microscopic), endoscopic, or radiographic. They should be 
of high quality (300 PPI or greater, clear, and in good focus) and illustrate the diagnosis well. 
 
Photographs: Remove all names and all other patient identifiers from photos and radiographic studies. 
 
Line Art and Graphs: Graphs, charts and other line art may be reformatted and/or redrawn by our Graphics 
staff for consistency with the overall style of the AGA Institute journals. Please be sure that any graphs or line 
art you submit are at a resolution of at least 300 ppi so that they are readable to reviewers. 
 
Figure Legends: Please do not embed or flatten the text into the image files. Figure legends should be included 
in the manuscript body, immediately before the references, or typed and submitted in .doc (Word document) 
or .rtf (rich text format). This text will be reformatted in the style of the AGA Institute journals. 
 
Gel Electrophoresis Labels: Protein molecular weight or DNA marker sizes must be indicated on all figure 




Preferred Figure File Formats: The preferred formats for figure files are tiff (.tif) and jpeg (.jpg). For questions 
regarding the conversion of other file formats to .jpg or .tif, please view our Figure Submission FAQs. 
 
Accepted Figure File Formats: Other acceptable file formats include: .bmp, .gif, .pbm, .pcx, .png, .pct, .msp, 
.tif, .eps, .xbm, .psd, .ai, .indd, .pdf, and .tga files. When sending image files, please do not embed them in 
Word. You may submit mixed file formats (image1.jpg, image2.tif, image3.eps, etc.). 
 
Image File Formats not Supported at this Time: Microsoft Word, Microsoft PowerPoint, Microsoft Excel 
Spreadsheets, ChemDraw, CorelDraw, Canvas, FreeHand, SigmaPlot, QuarkXpress, and Equation Editor. You 
may export image files from these programs as PDF, JPEG, or other acceptable file formats. For questions 
regarding the conversion of these file formats to our preferred formats, please view our Figure Submission 
FAQs. 
 
File Naming Convention: Figures should be named consecutively such as "figure 1.tif," "figure 2.jpg," etc., with 
the file extension appended (.tif, .jpg, .eps, etc). Each figure should be saved as a separate electronic file. 
 
Color Files: Figures should be submitted in the CMYK color space. Authors are encouraged to present color 
figures in a manner that will allow the data to be interpreted by colorblind readers. CGHy suggests that 
authors present dual-labeled images in green and magenta rather than in green and red. See the website of the 
Jfly data depository for Drosphila researchers (http://jfly.iam.u-tokyo.ac.jp/color/ ) for more information on 
how to make figures and presentations intelligible for a colorblind audience. 
 
Font: If your figures include text, an 8 to 10 point Arial font should be used. Acceptable fonts are "sans serif" 
fonts such as Helvetica, Arial, and Myriad. Examples of unacceptable fonts ("serif" fonts) are Times New 
Roman, Palatino, and Garamond. Lettering should begin with an upper case letter, followed by lower case 
lettering. 
 
Multiple Panel Figures: Please submit each panel (image) separately. However, you may submit a multiple 
panel version to suggest the order in which you would like the panels arranged. You may also include a 
written, suggested layout. Each individual panel should be of the highest possible quality (300 PPI or higher) 
at actual print size. 
 
Cost: Authors will be required to pay for the printing of color figures ($650 for the first color figure and $100 
each for additional figures). If the manuscript is reviewed with color figures, it must be published with color 
figures with printing fees paid for by the author. If the author does not wish to pay for printing color figures, 
then the figures must be uploaded in grayscale or black-and-white only to allow review of the data as they 
will ultimately be published in print. Authors may include color images to be published online only by 






We encourage you to submit non-essential figures or portions of your manuscript as supplementary material for online-
only publication, as our readership highly values supplementary materials. However, please note that the following 
items MUST be within the main text and not provided as supplemental information: 1) important materials and 
methods 2) references cited in the main text. Also, authors who offer supplementary information must ensure those 
materials are readily available upon request. 
 
The portions of your manuscript that you would like to be included as supplementary material (including figures and 
tables) should be uploaded separately from the manuscript as "supporting documents." The supplementary material will 





A graphical abstract is a single, concise visual summary of the main findings of the original research full-length article. 
For ease of understanding, the graphical abstract should read clearly from top to bottom or left to right. 
 
Specifications 
Please download and use our PowerPoint template to assist in the creation of your graphical abstract. The template file 
is the proper size and contains the required font style and size, plus other stylistic elements to ensure a clean and 
uniform look to your abstract. If you elect not to use our template, please adhere to the following guidelines: 
 
Image size: minimum of 2 inches high by 5 inches wide at 300 PPI. Larger images are allowed, but please use the same 
ratio (2" high x 5" wide). Please note that your image will be scaled proportionally to fit in a 2 x 5 rectangle. 
• Font: Arial font only will be accepted. 
• File type: preferred file types are TIFF, EPS, PDF, or PowerPoint. 
• No additional text, outline or synopsis can be included. Any text or label must be part of the image file. Please do 




All graphical abstracts must: 
• Be a clear, visual representation of the main findings of the article 
• Use text sparingly 
• Avoid distracting or cluttering components 






The use of color is encouraged; however graphical abstracts are subject to the same color figure charges as the rest of 
your article. If you do not wish to have your graphical abstract printed in color, please provide two versions-one in 
color for online publication only and one in black and white/grayscale for publication in print. 
 
Graphics Support 
The editorial office is not able to provide graphics support at this time. Authors are responsible for obtaining permission 
to use any images that they include from outside sources, including articles, web pages, stock photo sites, or Google 
image searches. Any needed permissions must be submitted along with your graphical abstract or identified in the 
Acknowledgements section of your manuscript. 
 
PREPRINT SERVER POLICY 
CGH allows manuscript submissions to have been posted to a preprint server, with the following stipulations: 
• Authors must retain copyright for the manuscript so that it may be transferred to AGA or to Elsevier if the 
manuscript is accepted, per the journal's copyright policy. 
• The preprint cannot be updated while the manuscript is under review and cannot be updated if it is accepted for 
publication in the journal, even if the preprint server directs the author to do otherwise. 
• If a manuscript is already submitted to an AGA journal and is under review, that manuscript may be submitted to a 
preprint server at any time before the article is accepted so that it may be considered as a published work in grant 
applications. As above, that preprint cannot be edited or updated while under review and cannot be updated if it is 
accepted for publication in the journal. 
• Publication of a preprint must be noted on the title page of the submission, with the preprint DOI included. 
• Because of the potential impact on patient care, preprints of a clinical nature are discouraged but will be considered; 
your decision to post a clinically oriented paper to a preprint server may impact ultimate acceptance. 
• We only allow submissions of preprint papers from platforms that allow you to update your record with a link to 
the published article (for example, bioRxiv). 
 
 
REPORTING CLINICAL TRIALS 
Registration 
 
In according with the guidelines set for by the ICMJE (http://www.icmje.org/recommendations/browse/publishing-
and-editorial-issues/clinical-trail-registration.html), authors of manuscripts involving clinical trials must provide full 
registration of their clinical trial(s). A clinical trial is defined as any research project that prospectively assigns human 
subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical 
intervention and a health outcome. The trial must have at least one prospectively assigned concurrent control or 
comparison group in order to trigger the requirement for registration. 
 
Appropriate online registries 
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include http://www.clinicaltrials.gov, http://www.isrctn.org, http://www.umin.ac.jp/ctr/index.htm, https://www.anzctr
.org.au, http://www.trialregister.nl or any primary registers that participate in the World Health Organization's 
International Clinical Trial Platform. 
 
The clinical trial registry web site and the clinical trial number must be included at the end of the Conclusions section 
in the abstract (this information will not count toward the 260 word limit). Example: ClincialTrials.gov, number 
NCT002209456. This information must also be provided in the manuscript management system upon submission. 
 
Randomized Controlled Trials 
 
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, 
authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients 
through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed 
description of the randomization procedure. The CONSORT checklist and template flow diagram can be found 
on http://www.consort-statement.org. Manuscripts that fail to comply with CONSORT guidelines will not be reviewed 
for publication. Authors must include Randomized Controlled Trial on the title of the manuscript. 
 
Access to Study Data 
 
In the methods section, a statement must be made that all authors had access to the study data and had reviewed and 
approved the final manuscript. 
 
MANUSCRIPT PROCESSING AND REVIEW 
 
Submissions. The Editorial Office receives over 2,700 manuscripts a year. Each new manuscript receives a unique 
number, and information on the manuscript is recorded on the Editorial Office computer network. The editorial staff 
releases information on manuscripts only to authors. The Editorial Office will e-mail a letter to the corresponding 
author acknowledging receipt of a manuscript, whether new or a resubmission. All manuscripts should be submitted 
online at http://www.editorialmanager.com/cgh. 
 
Review process. Each manuscript is assigned to an Associate Editor who has expertise on the subject of the manuscript. 
After review by the Associate Editor, if the manuscript is judged to be appropriate and competitive for publication 
in CGH, it is sent to experts in the appropriate area for peer review. The Associate Editor chooses two or three 
reviewers, who remain anonymous. Authors are encouraged to suggest an Associate Editor and three to four reviewers 
in the cover letter, though final assignments are at the discretion of the editor. 
 
Reviewers provide comments for the editor and for the authors. The Journal expects reviewers to treat manuscripts as 
confidential communications and not to use the content for their own purposes or make copies of the manuscripts. 
Reviewers are also expected to declare to the editor any possible conflicts of interest. 
 
Decisions. The single most important criterion for acceptance is the originality of the work. However, a decision to 
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accept a manuscript is not based solely on the scientific validity of its content. Other factors affecting decisions include 
the extent and importance of new information in the paper compared with that in other papers being considered, the 
Journal's need to represent a wide range of topics, and the overall suitability for CGH. Decision letters usually, but not 
always, convey all factors considered for a particular decision. Occasionally, the comments to the authors may appear to 
be inconsistent with the editorial decision, which takes into consideration reviewers' comments to the editor, as well as 
the additional factors listed above. 
 




Accepted manuscripts are sent to the publisher, Elsevier, and indexed on PubMed soon after acceptance. Within five to 
seven business days, they will be uploaded to CGH www.cghjournal.org under "Articles in Press" for preprint viewing 
by subscribers. Once authors have had the opportunity to review proofs of their manuscripts, these author-corrected 
proofs will replace the uncorrected proofs, followed by the final articles on PubMed. 
 
There is a press embargo for all studies published in CGH until they are posted online in our Articles in Press section. 
Studies cannot be publicized as accepted manuscripts or uncorrected proofs. In the event a corrected proof is not posted 
online, the embargo will be lifted at 3 p.m. ET the day of online publication. Please see our embargo policy 
at http://cghjournal.org/content/embargo for more details. 
 
Manuscripts are copyedited to make them consistent with Journal style; if a particular section in the manuscript is not 
clear or requires additional information, the copyeditor will direct questions to the author. These questions, or "author 
queries," will appear in the margins of the proofs that are sent to the author. All abstracts and titles will be reviewed 
and modified by the Journal's science editor. Authors can review changes at the revision stage of their manuscripts. All 
line art will be reviewed and possibly modified by the Journal's graphics staff. Authors can review changes at the proof 
stage of their manuscripts. 
 
The time between acceptance and print publication is approximately three months. Articles are posted online as an 
article in press within one week. The corresponding author can expect proofs of the article approximately two months 
after acceptance. Authors receive proofs for the primary purpose of checking the accuracy of the typesetting; authors 
are not to revise or rewrite their articles at this stage. If after acceptance of their paper, authors become aware of 
important information they believe should be added to their manuscript, they should contact the editor of CGH. 
 
Authors are required to return proofs to the publisher within 48 hours. If changes are not returned within 48 hours, the 
manuscript will move forward in the production process. 
 
Reprints. Forms for ordering article reprints will be sent with proofs to authors and should be returned with the 
corrected proofs. Authors do not receive free reprints, and therefore are responsible for ordering their own reprints 
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